| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 807 | 2024 | 11835 | 43.720 |
Why?
|
| Stroke Volume | 563 | 2024 | 5513 | 31.790 |
Why?
|
| Tetrazoles | 190 | 2024 | 901 | 22.680 |
Why?
|
| Angiotensin Receptor Antagonists | 172 | 2024 | 1025 | 19.950 |
Why?
|
| Ventricular Function, Left | 248 | 2024 | 3870 | 16.960 |
Why?
|
| Biphenyl Compounds | 184 | 2024 | 988 | 16.900 |
Why?
|
| Ventricular Dysfunction, Left | 158 | 2024 | 2129 | 16.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 127 | 2024 | 1521 | 10.880 |
Why?
|
| Enalapril | 51 | 2024 | 313 | 10.310 |
Why?
|
| Neprilysin | 61 | 2024 | 472 | 10.270 |
Why?
|
| Glucosides | 70 | 2024 | 536 | 9.960 |
Why?
|
| Benzhydryl Compounds | 81 | 2024 | 942 | 9.600 |
Why?
|
| Drug Combinations | 146 | 2024 | 2024 | 9.580 |
Why?
|
| Natriuretic Peptide, Brain | 102 | 2024 | 1705 | 9.360 |
Why?
|
| Spironolactone | 53 | 2024 | 411 | 9.350 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 61 | 2024 | 435 | 7.640 |
Why?
|
| Ventricular Remodeling | 67 | 2024 | 1259 | 7.490 |
Why?
|
| Peptide Fragments | 86 | 2024 | 5120 | 5.670 |
Why?
|
| Hypertrophy, Left Ventricular | 39 | 2023 | 853 | 5.610 |
Why?
|
| Hospitalization | 176 | 2024 | 10761 | 5.560 |
Why?
|
| Myocardial Infarction | 133 | 2024 | 11891 | 5.440 |
Why?
|
| Cardiac Resynchronization Therapy | 59 | 2024 | 556 | 5.440 |
Why?
|
| Echocardiography | 133 | 2024 | 4980 | 5.430 |
Why?
|
| Prealbumin | 19 | 2024 | 222 | 5.420 |
Why?
|
| Heart Failure, Diastolic | 14 | 2024 | 77 | 4.980 |
Why?
|
| Renal Insufficiency, Chronic | 54 | 2024 | 2296 | 4.710 |
Why?
|
| Defibrillators, Implantable | 60 | 2024 | 1499 | 4.680 |
Why?
|
| Amyloid Neuropathies, Familial | 13 | 2024 | 150 | 4.590 |
Why?
|
| Atrial Fibrillation | 58 | 2024 | 5201 | 4.290 |
Why?
|
| Aged | 649 | 2024 | 168995 | 4.180 |
Why?
|
| Atherosclerosis | 45 | 2024 | 3524 | 4.140 |
Why?
|
| Influenza Vaccines | 29 | 2024 | 770 | 4.010 |
Why?
|
| Influenza, Human | 33 | 2024 | 1532 | 3.980 |
Why?
|
| Humans | 1274 | 2024 | 760261 | 3.920 |
Why?
|
| Cardiovascular Diseases | 129 | 2024 | 15740 | 3.880 |
Why?
|
| Hypertension | 53 | 2023 | 8595 | 3.810 |
Why?
|
| Hematinics | 24 | 2023 | 281 | 3.780 |
Why?
|
| Double-Blind Method | 160 | 2024 | 12412 | 3.770 |
Why?
|
| Heart Ventricles | 60 | 2024 | 3811 | 3.760 |
Why?
|
| Heart Atria | 44 | 2024 | 1344 | 3.670 |
Why?
|
| Antihypertensive Agents | 48 | 2023 | 2063 | 3.580 |
Why?
|
| Benzimidazoles | 34 | 2020 | 858 | 3.510 |
Why?
|
| Male | 808 | 2024 | 359413 | 3.470 |
Why?
|
| Cardiomyopathies | 29 | 2024 | 1945 | 3.420 |
Why?
|
| Blood Pressure | 61 | 2024 | 8523 | 3.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 80 | 2024 | 12281 | 3.410 |
Why?
|
| Middle Aged | 604 | 2024 | 220175 | 3.370 |
Why?
|
| Glomerular Filtration Rate | 64 | 2024 | 2178 | 3.360 |
Why?
|
| Troponin T | 28 | 2023 | 774 | 3.320 |
Why?
|
| Female | 812 | 2024 | 391011 | 3.260 |
Why?
|
| Prognosis | 213 | 2024 | 29636 | 3.240 |
Why?
|
| Atrial Function, Left | 20 | 2024 | 186 | 3.190 |
Why?
|
| Echocardiography, Doppler | 26 | 2023 | 900 | 3.020 |
Why?
|
| Fumarates | 27 | 2020 | 131 | 2.970 |
Why?
|
| Randomized Controlled Trials as Topic | 90 | 2024 | 10340 | 2.970 |
Why?
|
| Anemia | 32 | 2023 | 1511 | 2.890 |
Why?
|
| Urea | 16 | 2024 | 445 | 2.870 |
Why?
|
| Naphthyridines | 4 | 2024 | 141 | 2.840 |
Why?
|
| Valine | 28 | 2014 | 409 | 2.830 |
Why?
|
| Erythropoietin | 17 | 2023 | 720 | 2.770 |
Why?
|
| Amyloidosis | 10 | 2024 | 818 | 2.720 |
Why?
|
| Treatment Outcome | 274 | 2024 | 64947 | 2.690 |
Why?
|
| Amides | 27 | 2020 | 448 | 2.580 |
Why?
|
| Death, Sudden, Cardiac | 31 | 2024 | 1572 | 2.550 |
Why?
|
| Diastole | 27 | 2021 | 788 | 2.550 |
Why?
|
| Renin-Angiotensin System | 21 | 2024 | 739 | 2.500 |
Why?
|
| Aged, 80 and over | 163 | 2024 | 58947 | 2.230 |
Why?
|
| Risk Factors | 236 | 2024 | 74269 | 2.170 |
Why?
|
| Prospective Studies | 168 | 2024 | 54263 | 2.130 |
Why?
|
| Hypotension | 12 | 2024 | 883 | 2.130 |
Why?
|
| Heart Failure, Systolic | 9 | 2023 | 136 | 2.110 |
Why?
|
| Cause of Death | 51 | 2024 | 3723 | 2.050 |
Why?
|
| Risk Assessment | 105 | 2024 | 24086 | 1.990 |
Why?
|
| Diabetes Mellitus | 31 | 2024 | 5884 | 1.970 |
Why?
|
| Kidney | 37 | 2024 | 7072 | 1.970 |
Why?
|
| Diuretics | 20 | 2023 | 612 | 1.850 |
Why?
|
| Natriuretic Peptides | 11 | 2023 | 156 | 1.790 |
Why?
|
| Follow-Up Studies | 136 | 2024 | 39254 | 1.780 |
Why?
|
| Proportional Hazards Models | 92 | 2024 | 12532 | 1.760 |
Why?
|
| Kidney Diseases | 24 | 2023 | 2093 | 1.720 |
Why?
|
| Cardiovascular Agents | 16 | 2024 | 864 | 1.710 |
Why?
|
| Bundle-Branch Block | 20 | 2020 | 281 | 1.700 |
Why?
|
| Prediabetic State | 8 | 2023 | 550 | 1.700 |
Why?
|
| Cardiomyopathy, Hypertrophic | 19 | 2024 | 1300 | 1.700 |
Why?
|
| Systole | 28 | 2024 | 947 | 1.690 |
Why?
|
| Stroke | 52 | 2023 | 9945 | 1.660 |
Why?
|
| Ventricular Dysfunction, Right | 14 | 2023 | 615 | 1.620 |
Why?
|
| Renin | 17 | 2022 | 636 | 1.610 |
Why?
|
| Pulmonary Edema | 8 | 2024 | 409 | 1.580 |
Why?
|
| Heart | 16 | 2023 | 4392 | 1.580 |
Why?
|
| Quality of Life | 59 | 2024 | 13300 | 1.530 |
Why?
|
| Hyperkalemia | 14 | 2023 | 231 | 1.510 |
Why?
|
| Captopril | 16 | 2015 | 266 | 1.510 |
Why?
|
| Kidney Failure, Chronic | 22 | 2024 | 2469 | 1.450 |
Why?
|
| Ramipril | 15 | 2024 | 97 | 1.440 |
Why?
|
| Time Factors | 122 | 2024 | 40133 | 1.430 |
Why?
|
| Endpoint Determination | 15 | 2020 | 597 | 1.420 |
Why?
|
| Albuminuria | 15 | 2023 | 659 | 1.400 |
Why?
|
| Protease Inhibitors | 6 | 2020 | 755 | 1.390 |
Why?
|
| Clinical Trials as Topic | 41 | 2024 | 8058 | 1.390 |
Why?
|
| Diabetes Complications | 14 | 2020 | 1342 | 1.380 |
Why?
|
| Myocardial Contraction | 21 | 2024 | 1516 | 1.370 |
Why?
|
| Electric Countershock | 15 | 2024 | 537 | 1.350 |
Why?
|
| Sex Factors | 39 | 2024 | 10530 | 1.300 |
Why?
|
| United States | 138 | 2024 | 72363 | 1.290 |
Why?
|
| Angiotensins | 13 | 2024 | 143 | 1.260 |
Why?
|
| Heart Rate | 15 | 2023 | 4169 | 1.240 |
Why?
|
| Coronavirus Infections | 12 | 2020 | 3086 | 1.230 |
Why?
|
| Pneumonia, Viral | 12 | 2020 | 3206 | 1.220 |
Why?
|
| Survival Rate | 67 | 2022 | 12806 | 1.200 |
Why?
|
| Kaplan-Meier Estimate | 53 | 2024 | 6545 | 1.190 |
Why?
|
| Tachycardia, Ventricular | 19 | 2023 | 1302 | 1.190 |
Why?
|
| Troponin I | 7 | 2024 | 634 | 1.170 |
Why?
|
| Dipeptides | 3 | 2019 | 410 | 1.170 |
Why?
|
| Electrocardiography | 37 | 2021 | 6413 | 1.160 |
Why?
|
| Ventricular Pressure | 3 | 2021 | 204 | 1.150 |
Why?
|
| Incidence | 64 | 2023 | 21378 | 1.140 |
Why?
|
| Blood Glucose | 17 | 2024 | 6375 | 1.100 |
Why?
|
| Drug Therapy, Combination | 40 | 2024 | 6499 | 1.070 |
Why?
|
| Research Design | 24 | 2023 | 6181 | 1.050 |
Why?
|
| Ventricular Function, Right | 11 | 2024 | 610 | 1.040 |
Why?
|
| Predictive Value of Tests | 57 | 2024 | 15273 | 1.020 |
Why?
|
| Heart Diseases | 7 | 2022 | 2809 | 1.010 |
Why?
|
| Vaccination | 21 | 2024 | 3360 | 0.990 |
Why?
|
| Diabetic Angiopathies | 7 | 2020 | 822 | 0.990 |
Why?
|
| Comorbidity | 45 | 2023 | 10552 | 0.990 |
Why?
|
| Europe | 30 | 2024 | 3433 | 0.980 |
Why?
|
| Obesity | 20 | 2024 | 12915 | 0.980 |
Why?
|
| Exercise Tolerance | 15 | 2024 | 826 | 0.970 |
Why?
|
| Disease Progression | 46 | 2024 | 13505 | 0.970 |
Why?
|
| Ventricular Fibrillation | 11 | 2023 | 539 | 0.970 |
Why?
|
| RNA, Small Interfering | 5 | 2023 | 3443 | 0.960 |
Why?
|
| Cardiomyopathy, Restrictive | 2 | 2015 | 62 | 0.960 |
Why?
|
| Furosemide | 4 | 2023 | 170 | 0.940 |
Why?
|
| Cardiac Myosins | 7 | 2024 | 124 | 0.940 |
Why?
|
| Death, Sudden | 5 | 2022 | 302 | 0.940 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 6 | 2013 | 321 | 0.920 |
Why?
|
| Creatinine | 29 | 2024 | 1906 | 0.920 |
Why?
|
| Extravascular Lung Water | 2 | 2014 | 20 | 0.920 |
Why?
|
| Cardiotonic Agents | 10 | 2020 | 546 | 0.910 |
Why?
|
| Dietary Carbohydrates | 3 | 2018 | 893 | 0.900 |
Why?
|
| Coronary Disease | 17 | 2019 | 5993 | 0.890 |
Why?
|
| Health Status | 17 | 2023 | 4081 | 0.880 |
Why?
|
| Multivariate Analysis | 45 | 2020 | 12156 | 0.850 |
Why?
|
| Myocardium | 20 | 2023 | 4688 | 0.850 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 159 | 0.850 |
Why?
|
| Malnutrition | 2 | 2019 | 638 | 0.840 |
Why?
|
| Smoking | 12 | 2022 | 9070 | 0.840 |
Why?
|
| Mitral Valve Insufficiency | 8 | 2024 | 1419 | 0.830 |
Why?
|
| Ultrasonography | 37 | 2021 | 5960 | 0.830 |
Why?
|
| Amyloidosis, Familial | 2 | 2023 | 16 | 0.820 |
Why?
|
| Dose-Response Relationship, Drug | 32 | 2024 | 10829 | 0.800 |
Why?
|
| Coronary Artery Disease | 20 | 2023 | 6661 | 0.790 |
Why?
|
| Benzylamines | 8 | 2024 | 248 | 0.790 |
Why?
|
| Hemoglobins | 12 | 2023 | 1521 | 0.790 |
Why?
|
| Barbiturates | 4 | 2022 | 113 | 0.780 |
Why?
|
| Uracil | 8 | 2024 | 207 | 0.770 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 5 | 2020 | 38 | 0.760 |
Why?
|
| Severity of Illness Index | 47 | 2021 | 15827 | 0.750 |
Why?
|
| Ergocalciferols | 5 | 2013 | 111 | 0.750 |
Why?
|
| Alcohol Drinking | 6 | 2019 | 4012 | 0.740 |
Why?
|
| Heart Arrest | 9 | 2021 | 1506 | 0.740 |
Why?
|
| Pandemics | 17 | 2023 | 8621 | 0.740 |
Why?
|
| Age Factors | 36 | 2021 | 18415 | 0.740 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 10 | 2023 | 3223 | 0.740 |
Why?
|
| Mortality | 13 | 2024 | 2916 | 0.730 |
Why?
|
| Prevalence | 40 | 2024 | 15687 | 0.730 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2021 | 859 | 0.720 |
Why?
|
| Adrenergic beta-Antagonists | 16 | 2023 | 1256 | 0.720 |
Why?
|
| Hypoglycemic Agents | 18 | 2024 | 3149 | 0.720 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2024 | 96 | 0.700 |
Why?
|
| Pyridines | 6 | 2019 | 2877 | 0.700 |
Why?
|
| Renal Dialysis | 10 | 2024 | 1802 | 0.700 |
Why?
|
| Cardiac Volume | 6 | 2014 | 199 | 0.680 |
Why?
|
| Cardiology | 8 | 2023 | 1723 | 0.680 |
Why?
|
| Dyspnea | 5 | 2023 | 1352 | 0.670 |
Why?
|
| North America | 9 | 2024 | 1282 | 0.660 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 361 | 0.660 |
Why?
|
| Glycine | 5 | 2024 | 663 | 0.650 |
Why?
|
| Drug Labeling | 1 | 2021 | 251 | 0.650 |
Why?
|
| Antiemetics | 2 | 2018 | 187 | 0.650 |
Why?
|
| Hyperaldosteronism | 2 | 2022 | 244 | 0.650 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2018 | 13 | 0.650 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2022 | 206 | 0.630 |
Why?
|
| Hyperemia | 2 | 2019 | 221 | 0.630 |
Why?
|
| Uric Acid | 4 | 2023 | 807 | 0.630 |
Why?
|
| Body Mass Index | 18 | 2022 | 12901 | 0.630 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2018 | 112 | 0.620 |
Why?
|
| Migraine Disorders | 14 | 2006 | 1693 | 0.620 |
Why?
|
| Diabetic Nephropathies | 6 | 2023 | 988 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 12 | 2024 | 7468 | 0.610 |
Why?
|
| Blood Pressure Determination | 3 | 2020 | 641 | 0.610 |
Why?
|
| Indoles | 12 | 2019 | 1830 | 0.600 |
Why?
|
| Outpatients | 6 | 2024 | 1606 | 0.600 |
Why?
|
| Acute Coronary Syndrome | 11 | 2022 | 2362 | 0.600 |
Why?
|
| Cohort Studies | 52 | 2023 | 41317 | 0.600 |
Why?
|
| Ondansetron | 1 | 2018 | 95 | 0.590 |
Why?
|
| Nausea | 2 | 2018 | 677 | 0.590 |
Why?
|
| Chronic Disease | 35 | 2024 | 9283 | 0.580 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 401 | 0.580 |
Why?
|
| Adiposity | 2 | 2018 | 1851 | 0.570 |
Why?
|
| Apolipoprotein E4 | 1 | 2021 | 708 | 0.570 |
Why?
|
| Hemodynamics | 18 | 2021 | 4169 | 0.570 |
Why?
|
| Echocardiography, Doppler, Color | 6 | 2014 | 354 | 0.570 |
Why?
|
| Models, Cardiovascular | 4 | 2024 | 974 | 0.570 |
Why?
|
| Vascular Diseases | 3 | 2022 | 1180 | 0.560 |
Why?
|
| Sulfonamides | 6 | 2014 | 1973 | 0.560 |
Why?
|
| Adult | 141 | 2024 | 219847 | 0.560 |
Why?
|
| Lung | 13 | 2023 | 9989 | 0.540 |
Why?
|
| Atrial Natriuretic Factor | 6 | 2022 | 350 | 0.530 |
Why?
|
| Heart Valve Diseases | 4 | 2022 | 1047 | 0.530 |
Why?
|
| Exercise | 7 | 2024 | 5783 | 0.530 |
Why?
|
| Polypharmacy | 3 | 2024 | 307 | 0.530 |
Why?
|
| Ferritins | 3 | 2022 | 598 | 0.520 |
Why?
|
| Retinal Artery | 1 | 2016 | 109 | 0.520 |
Why?
|
| Myocardial Revascularization | 6 | 2017 | 841 | 0.520 |
Why?
|
| Arrhythmias, Cardiac | 11 | 2022 | 2255 | 0.520 |
Why?
|
| Survival Analysis | 26 | 2022 | 10185 | 0.510 |
Why?
|
| Cardiac Pacing, Artificial | 4 | 2019 | 865 | 0.510 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 1174 | 0.500 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2015 | 269 | 0.500 |
Why?
|
| Plant Stems | 1 | 2015 | 18 | 0.500 |
Why?
|
| Cost of Illness | 3 | 2024 | 1940 | 0.490 |
Why?
|
| Longevity | 2 | 2020 | 1050 | 0.490 |
Why?
|
| Prehypertension | 1 | 2015 | 63 | 0.490 |
Why?
|
| Single-Blind Method | 10 | 2019 | 1577 | 0.490 |
Why?
|
| Vomiting | 1 | 2018 | 649 | 0.490 |
Why?
|
| Saccharum | 1 | 2015 | 20 | 0.490 |
Why?
|
| Troponin | 5 | 2019 | 516 | 0.490 |
Why?
|
| Hypoglycemia | 1 | 2022 | 888 | 0.490 |
Why?
|
| Genes, Plant | 1 | 2015 | 128 | 0.480 |
Why?
|
| Losartan | 4 | 2012 | 258 | 0.480 |
Why?
|
| Canada | 15 | 2019 | 2128 | 0.480 |
Why?
|
| Linear Models | 17 | 2019 | 5876 | 0.470 |
Why?
|
| Echocardiography, Three-Dimensional | 3 | 2018 | 613 | 0.470 |
Why?
|
| Placebos | 9 | 2020 | 1672 | 0.470 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2023 | 1583 | 0.470 |
Why?
|
| Receptors, Angiotensin | 7 | 2024 | 141 | 0.470 |
Why?
|
| Point-of-Care Systems | 2 | 2014 | 1208 | 0.470 |
Why?
|
| Myocardial Ischemia | 8 | 2023 | 2161 | 0.470 |
Why?
|
| Sucrose | 1 | 2015 | 156 | 0.470 |
Why?
|
| Hypokalemia | 6 | 2019 | 153 | 0.460 |
Why?
|
| Leprosy | 3 | 2000 | 129 | 0.460 |
Why?
|
| Multicenter Studies as Topic | 11 | 2022 | 1723 | 0.460 |
Why?
|
| Internationality | 7 | 2019 | 1005 | 0.460 |
Why?
|
| Delivery, Obstetric | 1 | 2021 | 933 | 0.450 |
Why?
|
| Organ Size | 15 | 2024 | 2249 | 0.450 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 163 | 0.450 |
Why?
|
| Heart Function Tests | 3 | 2012 | 319 | 0.450 |
Why?
|
| United States Food and Drug Administration | 2 | 2021 | 1675 | 0.450 |
Why?
|
| Chi-Square Distribution | 12 | 2017 | 3466 | 0.450 |
Why?
|
| Registries | 16 | 2024 | 8449 | 0.450 |
Why?
|
| Cardiac Output, Low | 4 | 2006 | 192 | 0.440 |
Why?
|
| Pyrazoles | 5 | 2016 | 1992 | 0.440 |
Why?
|
| Retinal Vessels | 1 | 2019 | 836 | 0.440 |
Why?
|
| Galectin 3 | 2 | 2016 | 240 | 0.440 |
Why?
|
| Vasodilator Agents | 5 | 2023 | 977 | 0.440 |
Why?
|
| Polyneuropathies | 4 | 2024 | 137 | 0.430 |
Why?
|
| Hypertrophy, Right Ventricular | 3 | 2015 | 107 | 0.420 |
Why?
|
| Pyrimidines | 7 | 2020 | 3011 | 0.420 |
Why?
|
| Hospital Mortality | 11 | 2023 | 5420 | 0.420 |
Why?
|
| Aftercare | 6 | 2023 | 918 | 0.420 |
Why?
|
| Health Status Indicators | 3 | 2015 | 968 | 0.420 |
Why?
|
| Retrospective Studies | 60 | 2024 | 80301 | 0.420 |
Why?
|
| Plant Proteins | 1 | 2015 | 370 | 0.410 |
Why?
|
| India | 20 | 2012 | 2346 | 0.400 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2012 | 114 | 0.400 |
Why?
|
| Risk | 19 | 2017 | 9629 | 0.400 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2023 | 150 | 0.400 |
Why?
|
| Sodium | 11 | 2023 | 1601 | 0.390 |
Why?
|
| Population Surveillance | 5 | 2017 | 2609 | 0.390 |
Why?
|
| Nitroprusside | 1 | 2012 | 273 | 0.390 |
Why?
|
| Headache | 8 | 2001 | 1249 | 0.390 |
Why?
|
| Social Behavior | 1 | 2018 | 1130 | 0.390 |
Why?
|
| Morbidity | 13 | 2020 | 1765 | 0.390 |
Why?
|
| Recurrence | 17 | 2020 | 8487 | 0.380 |
Why?
|
| Cardiomegaly | 4 | 2019 | 593 | 0.380 |
Why?
|
| Acute Kidney Injury | 8 | 2024 | 1935 | 0.380 |
Why?
|
| Critical Care | 2 | 2021 | 2699 | 0.380 |
Why?
|
| Hypercholesterolemia | 2 | 2018 | 1155 | 0.380 |
Why?
|
| Organ Transplantation | 1 | 2021 | 1150 | 0.380 |
Why?
|
| Motor Activity | 3 | 2015 | 2687 | 0.380 |
Why?
|
| Sympathetic Nervous System | 2 | 2020 | 519 | 0.380 |
Why?
|
| Cardiomyopathy, Dilated | 6 | 2023 | 819 | 0.370 |
Why?
|
| New York | 3 | 2023 | 874 | 0.370 |
Why?
|
| Death | 4 | 2020 | 678 | 0.370 |
Why?
|
| Heart Conduction System | 5 | 2020 | 1016 | 0.370 |
Why?
|
| Dexamethasone | 1 | 2018 | 1928 | 0.370 |
Why?
|
| Inpatients | 4 | 2023 | 2578 | 0.360 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2013 | 389 | 0.360 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2021 | 3335 | 0.360 |
Why?
|
| Health Status Disparities | 5 | 2020 | 1819 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 7 | 2013 | 2282 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 5644 | 0.350 |
Why?
|
| Patient Discharge | 8 | 2023 | 3475 | 0.350 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2021 | 2127 | 0.350 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2009 | 1894 | 0.350 |
Why?
|
| Denmark | 9 | 2024 | 759 | 0.350 |
Why?
|
| Potassium | 8 | 2021 | 1318 | 0.340 |
Why?
|
| alpha-Galactosidase | 1 | 2010 | 55 | 0.340 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2024 | 355 | 0.340 |
Why?
|
| Cardiovascular System | 6 | 2023 | 850 | 0.340 |
Why?
|
| Argentina | 4 | 2018 | 245 | 0.340 |
Why?
|
| Pulmonary Embolism | 4 | 2012 | 2544 | 0.340 |
Why?
|
| Hypertension, Pulmonary | 8 | 2020 | 1570 | 0.340 |
Why?
|
| Graft vs Host Disease | 7 | 2023 | 3023 | 0.340 |
Why?
|
| Growth Differentiation Factor 15 | 2 | 2023 | 192 | 0.330 |
Why?
|
| Prostaglandin Antagonists | 1 | 2009 | 28 | 0.330 |
Why?
|
| P-Selectin | 2 | 2023 | 600 | 0.330 |
Why?
|
| Receptors, Calcitriol | 2 | 2011 | 359 | 0.330 |
Why?
|
| Fabry Disease | 1 | 2010 | 85 | 0.330 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 8 | 2024 | 122 | 0.330 |
Why?
|
| Inflammation | 5 | 2024 | 10757 | 0.330 |
Why?
|
| Metformin | 3 | 2023 | 912 | 0.330 |
Why?
|
| Sex Distribution | 7 | 2015 | 2295 | 0.320 |
Why?
|
| Brazil | 5 | 2024 | 1214 | 0.320 |
Why?
|
| Physical Examination | 4 | 2019 | 1244 | 0.310 |
Why?
|
| Angioedema | 2 | 2020 | 192 | 0.310 |
Why?
|
| HIV Infections | 15 | 2012 | 17159 | 0.310 |
Why?
|
| Recovery of Function | 10 | 2020 | 2982 | 0.310 |
Why?
|
| Cross-Sectional Studies | 21 | 2023 | 25928 | 0.310 |
Why?
|
| Cost-Benefit Analysis | 7 | 2024 | 5507 | 0.310 |
Why?
|
| Acute Disease | 14 | 2024 | 7268 | 0.300 |
Why?
|
| Pneumonia | 5 | 2024 | 2138 | 0.300 |
Why?
|
| Reproducibility of Results | 19 | 2022 | 20048 | 0.300 |
Why?
|
| Sex Characteristics | 6 | 2023 | 2627 | 0.300 |
Why?
|
| Aging | 3 | 2016 | 8641 | 0.300 |
Why?
|
| Prostaglandins | 1 | 2009 | 398 | 0.300 |
Why?
|
| Algorithms | 6 | 2024 | 13967 | 0.300 |
Why?
|
| Extracellular Matrix | 5 | 2020 | 1726 | 0.300 |
Why?
|
| Vagus Nerve Stimulation | 3 | 2017 | 224 | 0.290 |
Why?
|
| Chagas Cardiomyopathy | 2 | 2018 | 71 | 0.290 |
Why?
|
| Vasodilation | 1 | 2012 | 964 | 0.290 |
Why?
|
| Aortic Valve | 2 | 2018 | 1996 | 0.290 |
Why?
|
| Up-Regulation | 8 | 2021 | 4127 | 0.290 |
Why?
|
| Drug Administration Schedule | 7 | 2021 | 4900 | 0.290 |
Why?
|
| Data Interpretation, Statistical | 7 | 2018 | 2696 | 0.290 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2020 | 152 | 0.290 |
Why?
|
| Blindness | 3 | 2006 | 582 | 0.290 |
Why?
|
| Flavins | 2 | 2023 | 18 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2018 | 3967 | 0.280 |
Why?
|
| Protein Precursors | 4 | 2020 | 1135 | 0.280 |
Why?
|
| Glucose | 7 | 2023 | 4361 | 0.280 |
Why?
|
| Angina Pectoris | 3 | 2015 | 969 | 0.280 |
Why?
|
| Analgesics | 2 | 2008 | 1066 | 0.270 |
Why?
|
| Dementia | 5 | 2022 | 2638 | 0.270 |
Why?
|
| Guanylate Cyclase | 3 | 2020 | 205 | 0.270 |
Why?
|
| AIDS-Related Opportunistic Infections | 5 | 2008 | 661 | 0.270 |
Why?
|
| Brain Ischemia | 2 | 2019 | 3127 | 0.270 |
Why?
|
| C-Reactive Protein | 8 | 2024 | 3822 | 0.270 |
Why?
|
| Aldosterone | 6 | 2022 | 868 | 0.270 |
Why?
|
| Sepsis | 2 | 2022 | 2594 | 0.270 |
Why?
|
| Kidney Function Tests | 5 | 2017 | 680 | 0.270 |
Why?
|
| Body Weight | 5 | 2016 | 4613 | 0.270 |
Why?
|
| Young Adult | 31 | 2024 | 58673 | 0.270 |
Why?
|
| Medicare | 11 | 2024 | 6771 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 2 | 2017 | 5784 | 0.260 |
Why?
|
| Vascular Resistance | 5 | 2016 | 932 | 0.260 |
Why?
|
| Peptides | 7 | 2020 | 4358 | 0.260 |
Why?
|
| Thiazepines | 1 | 2005 | 30 | 0.260 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2024 | 1038 | 0.260 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 884 | 0.260 |
Why?
|
| Exercise Test | 7 | 2024 | 2125 | 0.260 |
Why?
|
| Guideline Adherence | 2 | 2018 | 2283 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 1724 | 0.260 |
Why?
|
| Luciferases | 3 | 2023 | 716 | 0.260 |
Why?
|
| Reference Values | 11 | 2019 | 4920 | 0.250 |
Why?
|
| Triglycerides | 4 | 2021 | 2476 | 0.250 |
Why?
|
| Hyperglycemia | 3 | 2020 | 1380 | 0.250 |
Why?
|
| Case-Control Studies | 11 | 2020 | 22041 | 0.250 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2022 | 584 | 0.250 |
Why?
|
| Administration, Oral | 8 | 2024 | 4044 | 0.250 |
Why?
|
| Cholesterol | 5 | 2021 | 2925 | 0.250 |
Why?
|
| Heterozygote | 4 | 2024 | 2797 | 0.250 |
Why?
|
| Epoetin Alfa | 2 | 2022 | 79 | 0.250 |
Why?
|
| Coronary Artery Bypass | 4 | 2022 | 2273 | 0.250 |
Why?
|
| Aortic Valve Stenosis | 2 | 2018 | 2064 | 0.240 |
Why?
|
| Iron | 4 | 2022 | 1786 | 0.240 |
Why?
|
| Eye Diseases | 2 | 2021 | 651 | 0.240 |
Why?
|
| Myocardial Reperfusion | 3 | 2006 | 347 | 0.240 |
Why?
|
| Insulin Resistance | 2 | 2021 | 3960 | 0.240 |
Why?
|
| Age Distribution | 8 | 2018 | 2893 | 0.240 |
Why?
|
| Radiopharmaceuticals | 2 | 2022 | 2633 | 0.240 |
Why?
|
| Diabetic Foot | 1 | 2008 | 381 | 0.240 |
Why?
|
| Longitudinal Studies | 14 | 2021 | 14482 | 0.240 |
Why?
|
| Adolescent | 47 | 2024 | 87747 | 0.240 |
Why?
|
| Sodium-Glucose Transport Proteins | 1 | 2024 | 13 | 0.240 |
Why?
|
| Sweden | 4 | 2020 | 1381 | 0.230 |
Why?
|
| Creatine | 1 | 2006 | 426 | 0.230 |
Why?
|
| Disease Management | 5 | 2024 | 2508 | 0.230 |
Why?
|
| Aldehyde Reductase | 1 | 2024 | 71 | 0.230 |
Why?
|
| Proteinuria | 2 | 2009 | 594 | 0.230 |
Why?
|
| Oxygen Consumption | 6 | 2024 | 1840 | 0.230 |
Why?
|
| Neoplasms | 6 | 2023 | 22066 | 0.230 |
Why?
|
| Probability | 3 | 2021 | 2476 | 0.230 |
Why?
|
| Coronary Vessels | 2 | 2013 | 3112 | 0.230 |
Why?
|
| Adenomatous Polyps | 1 | 2005 | 108 | 0.230 |
Why?
|
| Alginates | 2 | 2015 | 247 | 0.230 |
Why?
|
| Ventricular Outflow Obstruction | 2 | 2024 | 265 | 0.230 |
Why?
|
| Prostheses and Implants | 3 | 2019 | 1272 | 0.230 |
Why?
|
| Pulmonary Circulation | 3 | 2024 | 743 | 0.230 |
Why?
|
| Sequoia | 1 | 2023 | 6 | 0.230 |
Why?
|
| Contraceptive Agents | 1 | 2005 | 145 | 0.230 |
Why?
|
| Dihydropyridines | 1 | 2023 | 68 | 0.220 |
Why?
|
| Pyrans | 1 | 2023 | 49 | 0.220 |
Why?
|
| Digoxin | 2 | 2022 | 247 | 0.220 |
Why?
|
| Purinergic P2Y Receptor Agonists | 1 | 2023 | 5 | 0.220 |
Why?
|
| Sensitivity and Specificity | 12 | 2021 | 14656 | 0.220 |
Why?
|
| Vitamins | 1 | 2012 | 1635 | 0.220 |
Why?
|
| Hypovolemia | 1 | 2023 | 48 | 0.220 |
Why?
|
| Retinal Diseases | 2 | 2006 | 702 | 0.220 |
Why?
|
| Blood Specimen Collection | 2 | 2004 | 238 | 0.220 |
Why?
|
| Drug Monitoring | 2 | 2020 | 966 | 0.220 |
Why?
|
| Endothelium | 2 | 2020 | 764 | 0.220 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 364 | 0.210 |
Why?
|
| Erythrocyte Indices | 1 | 2023 | 145 | 0.210 |
Why?
|
| Odds Ratio | 12 | 2019 | 9712 | 0.210 |
Why?
|
| Diagnostic Imaging | 3 | 2015 | 3526 | 0.210 |
Why?
|
| Headache Disorders | 2 | 2005 | 148 | 0.210 |
Why?
|
| Mineralocorticoids | 1 | 2022 | 38 | 0.210 |
Why?
|
| Sexual Behavior | 3 | 2009 | 2080 | 0.210 |
Why?
|
| Carotid Arteries | 5 | 2016 | 951 | 0.210 |
Why?
|
| Sarcomeres | 3 | 2019 | 367 | 0.210 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2008 | 2197 | 0.210 |
Why?
|
| Frail Elderly | 2 | 2018 | 747 | 0.210 |
Why?
|
| Serologic Tests | 1 | 2004 | 383 | 0.200 |
Why?
|
| Myosins | 3 | 1994 | 405 | 0.200 |
Why?
|
| Atrial Flutter | 2 | 2022 | 258 | 0.200 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2002 | 63 | 0.200 |
Why?
|
| Immunization Schedule | 2 | 2024 | 225 | 0.200 |
Why?
|
| Phenotype | 12 | 2023 | 16543 | 0.200 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 1381 | 0.200 |
Why?
|
| Gene Expression | 2 | 2015 | 7592 | 0.200 |
Why?
|
| Education, Medical | 1 | 2014 | 1728 | 0.200 |
Why?
|
| Serum Amyloid P-Component | 1 | 2022 | 46 | 0.200 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 1130 | 0.200 |
Why?
|
| Carboxylic Acids | 1 | 2022 | 90 | 0.190 |
Why?
|
| Terminology as Topic | 2 | 2020 | 1534 | 0.190 |
Why?
|
| Erythropoiesis | 2 | 2023 | 682 | 0.190 |
Why?
|
| Prosthesis Implantation | 3 | 2023 | 593 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 15766 | 0.190 |
Why?
|
| Medication Therapy Management | 2 | 2021 | 132 | 0.190 |
Why?
|
| Carotid Artery Diseases | 2 | 2014 | 881 | 0.190 |
Why?
|
| Panophthalmitis | 1 | 2001 | 6 | 0.190 |
Why?
|
| Russia | 6 | 2018 | 381 | 0.190 |
Why?
|
| Rhizopus | 1 | 2001 | 22 | 0.190 |
Why?
|
| Positron-Emission Tomography | 4 | 2022 | 6457 | 0.190 |
Why?
|
| Brain Injury, Chronic | 1 | 2001 | 68 | 0.190 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 859 | 0.190 |
Why?
|
| Patient Readmission | 6 | 2024 | 3327 | 0.190 |
Why?
|
| Horner Syndrome | 1 | 2001 | 36 | 0.190 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 1899 | 0.190 |
Why?
|
| Transplantation Conditioning | 5 | 2019 | 1593 | 0.180 |
Why?
|
| Societies, Medical | 5 | 2021 | 3903 | 0.180 |
Why?
|
| Fibroblast Growth Factors | 2 | 2019 | 867 | 0.180 |
Why?
|
| Amlodipine | 3 | 2010 | 84 | 0.180 |
Why?
|
| Bone Density Conservation Agents | 3 | 2013 | 794 | 0.180 |
Why?
|
| Sumatriptan | 2 | 1998 | 66 | 0.180 |
Why?
|
| Income | 2 | 2019 | 1876 | 0.180 |
Why?
|
| Oligonucleotides | 1 | 2023 | 588 | 0.180 |
Why?
|
| Amyloidogenic Proteins | 1 | 2021 | 151 | 0.180 |
Why?
|
| Foot Ulcer | 1 | 2000 | 63 | 0.180 |
Why?
|
| American Heart Association | 2 | 2015 | 1081 | 0.180 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2001 | 49 | 0.180 |
Why?
|
| Head Injuries, Closed | 1 | 2001 | 133 | 0.180 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 8551 | 0.180 |
Why?
|
| Insulin | 4 | 2019 | 6592 | 0.180 |
Why?
|
| Consensus | 8 | 2022 | 3106 | 0.180 |
Why?
|
| Tachycardia | 2 | 2013 | 603 | 0.180 |
Why?
|
| Data Collection | 4 | 2018 | 3317 | 0.180 |
Why?
|
| Kidney Transplantation | 5 | 2017 | 4215 | 0.180 |
Why?
|
| Finite Element Analysis | 2 | 2001 | 428 | 0.170 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2024 | 459 | 0.170 |
Why?
|
| Thrombolytic Therapy | 4 | 2009 | 2108 | 0.170 |
Why?
|
| Pyrrolidines | 1 | 2022 | 338 | 0.170 |
Why?
|
| Galectins | 2 | 2020 | 282 | 0.170 |
Why?
|
| Eye Infections, Fungal | 1 | 2001 | 100 | 0.170 |
Why?
|
| Edema, Cardiac | 1 | 2019 | 19 | 0.170 |
Why?
|
| Mucormycosis | 1 | 2001 | 103 | 0.170 |
Why?
|
| Feeding Behavior | 2 | 2011 | 3185 | 0.170 |
Why?
|
| Virus Diseases | 2 | 2023 | 721 | 0.170 |
Why?
|
| Vital Capacity | 2 | 2022 | 965 | 0.170 |
Why?
|
| Stress, Physiological | 4 | 2015 | 1395 | 0.170 |
Why?
|
| Hyponatremia | 1 | 2022 | 281 | 0.170 |
Why?
|
| Cerebral Infarction | 4 | 2022 | 982 | 0.170 |
Why?
|
| Leprostatic Agents | 1 | 1998 | 15 | 0.160 |
Why?
|
| Exocytosis | 1 | 2020 | 322 | 0.160 |
Why?
|
| Patient Selection | 7 | 2017 | 4276 | 0.160 |
Why?
|
| Adenoma | 2 | 2006 | 2148 | 0.160 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2022 | 257 | 0.160 |
Why?
|
| Observer Variation | 6 | 2014 | 2596 | 0.160 |
Why?
|
| Mycobacterium leprae | 1 | 1998 | 97 | 0.160 |
Why?
|
| Calcium Channel Blockers | 4 | 2023 | 694 | 0.160 |
Why?
|
| Cystatin C | 4 | 2023 | 270 | 0.160 |
Why?
|
| Statistics as Topic | 8 | 2020 | 2363 | 0.160 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 418 | 0.150 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1999 | 155 | 0.150 |
Why?
|
| Atrial Appendage | 1 | 2022 | 292 | 0.150 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2009 | 628 | 0.150 |
Why?
|
| Biological Availability | 1 | 2019 | 395 | 0.150 |
Why?
|
| Brain Infarction | 2 | 2018 | 292 | 0.150 |
Why?
|
| Lipoproteins, LDL | 1 | 2021 | 641 | 0.150 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2020 | 345 | 0.150 |
Why?
|
| Drug Substitution | 2 | 2021 | 296 | 0.150 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 517 | 0.150 |
Why?
|
| Pacemaker, Artificial | 3 | 2019 | 815 | 0.150 |
Why?
|
| Canrenone | 1 | 2017 | 5 | 0.150 |
Why?
|
| Workflow | 1 | 2022 | 851 | 0.150 |
Why?
|
| Myeloablative Agonists | 1 | 2018 | 209 | 0.150 |
Why?
|
| Propanolamines | 1 | 2018 | 162 | 0.150 |
Why?
|
| Colorectal Neoplasms | 3 | 2006 | 6855 | 0.150 |
Why?
|
| Digitalis Glycosides | 1 | 2017 | 47 | 0.150 |
Why?
|
| Brachial Artery | 2 | 2016 | 368 | 0.150 |
Why?
|
| HIV-1 | 4 | 2012 | 6850 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2018 | 3804 | 0.150 |
Why?
|
| Computer Simulation | 3 | 2021 | 6210 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 14 | 5 | 2000 | 286 | 0.150 |
Why?
|
| Health Care Costs | 3 | 2024 | 3257 | 0.140 |
Why?
|
| Glucuronidase | 1 | 2019 | 203 | 0.140 |
Why?
|
| Peripheral Arterial Disease | 2 | 2023 | 1305 | 0.140 |
Why?
|
| Torsion, Mechanical | 1 | 2017 | 15 | 0.140 |
Why?
|
| Infusions, Intravenous | 2 | 2019 | 2235 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2015 | 1859 | 0.140 |
Why?
|
| Residence Characteristics | 3 | 2019 | 2058 | 0.140 |
Why?
|
| Menstruation Disturbances | 1 | 1998 | 144 | 0.140 |
Why?
|
| Risk Reduction Behavior | 5 | 2018 | 1109 | 0.140 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2018 | 122 | 0.140 |
Why?
|
| Area Under Curve | 3 | 2023 | 1635 | 0.140 |
Why?
|
| Georgia (Republic) | 4 | 2018 | 39 | 0.140 |
Why?
|
| Serine Endopeptidases | 2 | 2020 | 1021 | 0.140 |
Why?
|
| Pleural Effusion | 1 | 2020 | 343 | 0.140 |
Why?
|
| Lipoproteins, HDL | 1 | 2021 | 667 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 463 | 0.140 |
Why?
|
| Patient Dropouts | 2 | 2016 | 412 | 0.140 |
Why?
|
| von Willebrand Factor | 1 | 2020 | 673 | 0.140 |
Why?
|
| Foot Deformities, Acquired | 1 | 1996 | 27 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 3333 | 0.140 |
Why?
|
| Geriatric Assessment | 3 | 2019 | 1405 | 0.130 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2022 | 98 | 0.130 |
Why?
|
| Unsafe Sex | 2 | 2008 | 213 | 0.130 |
Why?
|
| Photography | 1 | 2019 | 530 | 0.130 |
Why?
|
| Sickle Cell Trait | 1 | 2016 | 85 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 2021 | 571 | 0.130 |
Why?
|
| Renal Insufficiency | 2 | 2016 | 820 | 0.130 |
Why?
|
| Dogs | 2 | 2020 | 3843 | 0.130 |
Why?
|
| Patients | 3 | 2021 | 906 | 0.130 |
Why?
|
| Atrial Function, Right | 1 | 2015 | 32 | 0.130 |
Why?
|
| Proteomics | 3 | 2024 | 3810 | 0.130 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 725 | 0.130 |
Why?
|
| Apolipoproteins E | 1 | 2021 | 1437 | 0.130 |
Why?
|
| Models, Statistical | 4 | 2020 | 5073 | 0.130 |
Why?
|
| Goals | 1 | 2021 | 708 | 0.130 |
Why?
|
| Gout | 1 | 2023 | 619 | 0.130 |
Why?
|
| Activities of Daily Living | 3 | 2023 | 2414 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 629 | 0.130 |
Why?
|
| Folic Acid | 2 | 2014 | 1309 | 0.130 |
Why?
|
| Geography | 2 | 2015 | 661 | 0.130 |
Why?
|
| Fibrosis | 3 | 2023 | 2042 | 0.130 |
Why?
|
| Leukoencephalopathies | 1 | 2018 | 249 | 0.130 |
Why?
|
| Amyloid | 1 | 2020 | 843 | 0.130 |
Why?
|
| Genetic Linkage | 7 | 2001 | 2381 | 0.130 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2012 | 749 | 0.130 |
Why?
|
| beta-Fructofuranosidase | 1 | 2015 | 12 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2020 | 754 | 0.120 |
Why?
|
| Patient Compliance | 3 | 2020 | 2689 | 0.120 |
Why?
|
| Treatment Failure | 6 | 2020 | 2646 | 0.120 |
Why?
|
| Nonprescription Drugs | 1 | 1996 | 118 | 0.120 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 608 | 0.120 |
Why?
|
| Crops, Agricultural | 1 | 2015 | 36 | 0.120 |
Why?
|
| Medical Records | 2 | 2019 | 1407 | 0.120 |
Why?
|
| Latin America | 3 | 2024 | 405 | 0.120 |
Why?
|
| Total Quality Management | 1 | 1996 | 264 | 0.120 |
Why?
|
| Confidence Intervals | 5 | 2012 | 2932 | 0.120 |
Why?
|
| Peripheral Nerves | 1 | 1998 | 475 | 0.120 |
Why?
|
| Hybridization, Genetic | 1 | 2015 | 103 | 0.120 |
Why?
|
| Diabetic Neuropathies | 1 | 2018 | 406 | 0.120 |
Why?
|
| Uncertainty | 1 | 2020 | 754 | 0.120 |
Why?
|
| Diabetic Retinopathy | 3 | 2018 | 1268 | 0.120 |
Why?
|
| Glucosyltransferases | 1 | 2015 | 96 | 0.120 |
Why?
|
| Polymorphism, Genetic | 4 | 2019 | 4286 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 1 | 1998 | 651 | 0.120 |
Why?
|
| Drug Design | 2 | 2017 | 1062 | 0.120 |
Why?
|
| Logistic Models | 9 | 2019 | 13311 | 0.120 |
Why?
|
| Elastic Modulus | 2 | 2013 | 210 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2018 | 397 | 0.120 |
Why?
|
| Cognition | 2 | 2024 | 6948 | 0.120 |
Why?
|
| Arthrodesis | 1 | 1996 | 186 | 0.120 |
Why?
|
| Avoidance Learning | 1 | 2016 | 248 | 0.120 |
Why?
|
| Arsenicals | 1 | 2014 | 117 | 0.120 |
Why?
|
| Leisure Activities | 1 | 2016 | 306 | 0.120 |
Why?
|
| Heart Auscultation | 1 | 2014 | 34 | 0.120 |
Why?
|
| Dihydroergotamine | 1 | 1994 | 19 | 0.120 |
Why?
|
| Diet Surveys | 1 | 2018 | 1161 | 0.120 |
Why?
|
| Least-Squares Analysis | 3 | 2020 | 369 | 0.120 |
Why?
|
| ROC Curve | 5 | 2019 | 3568 | 0.120 |
Why?
|
| Anti-HIV Agents | 4 | 2009 | 4492 | 0.120 |
Why?
|
| Intention to Treat Analysis | 3 | 2021 | 422 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 1230 | 0.120 |
Why?
|
| Injections, Subcutaneous | 2 | 2018 | 679 | 0.120 |
Why?
|
| Ventricular Function | 3 | 2013 | 408 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2008 | 5396 | 0.110 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2015 | 212 | 0.110 |
Why?
|
| Cimetidine | 1 | 1993 | 76 | 0.110 |
Why?
|
| Famotidine | 1 | 1993 | 17 | 0.110 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2024 | 87 | 0.110 |
Why?
|
| Hepatitis C Antibodies | 1 | 2014 | 145 | 0.110 |
Why?
|
| Resuscitation | 2 | 2011 | 662 | 0.110 |
Why?
|
| Hemorrhage | 2 | 2023 | 3604 | 0.110 |
Why?
|
| Tissue Survival | 1 | 2014 | 118 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2012 | 1880 | 0.110 |
Why?
|
| Stress, Mechanical | 6 | 2017 | 1666 | 0.110 |
Why?
|
| Kansas | 2 | 2023 | 39 | 0.110 |
Why?
|
| Mutation | 8 | 2019 | 29950 | 0.110 |
Why?
|
| Ambulatory Care | 2 | 2016 | 2783 | 0.110 |
Why?
|
| HIV | 1 | 2001 | 1579 | 0.110 |
Why?
|
| Respiratory Sounds | 3 | 2016 | 697 | 0.110 |
Why?
|
| Liver | 5 | 2023 | 7512 | 0.110 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2013 | 69 | 0.110 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 134 | 0.110 |
Why?
|
| Bacteria | 2 | 2024 | 2196 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2022 | 36247 | 0.110 |
Why?
|
| Forced Expiratory Volume | 1 | 2018 | 1810 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 2120 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2004 | 3159 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 3606 | 0.110 |
Why?
|
| Secondary Prevention | 4 | 2015 | 1548 | 0.110 |
Why?
|
| Second Messenger Systems | 1 | 2013 | 202 | 0.110 |
Why?
|
| Cerebrovascular Disorders | 3 | 1992 | 1500 | 0.110 |
Why?
|
| Patient Admission | 2 | 2019 | 1384 | 0.110 |
Why?
|
| Oxides | 1 | 2014 | 400 | 0.110 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 278 | 0.110 |
Why?
|
| Periodicals as Topic | 2 | 2022 | 1470 | 0.110 |
Why?
|
| Medicine | 1 | 2021 | 943 | 0.110 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2018 | 989 | 0.110 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2014 | 251 | 0.110 |
Why?
|
| Hemorheology | 1 | 2013 | 144 | 0.110 |
Why?
|
| Serotonin Receptor Agonists | 2 | 1993 | 151 | 0.110 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 180 | 0.110 |
Why?
|
| Muscle Cells | 2 | 2014 | 195 | 0.100 |
Why?
|
| Endothelium, Vascular | 2 | 2019 | 4437 | 0.100 |
Why?
|
| Creatine Kinase | 3 | 2006 | 691 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2020 | 2918 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 785 | 0.100 |
Why?
|
| Rural Health Services | 2 | 2008 | 381 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2016 | 922 | 0.100 |
Why?
|
| Independent Living | 1 | 2016 | 568 | 0.100 |
Why?
|
| Cyclic GMP | 1 | 2013 | 395 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2018 | 6361 | 0.100 |
Why?
|
| Government | 2 | 2023 | 160 | 0.100 |
Why?
|
| Causality | 2 | 2016 | 1241 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2000 | 1402 | 0.100 |
Why?
|
| Information Dissemination | 2 | 2021 | 1132 | 0.100 |
Why?
|
| Drug Costs | 1 | 2020 | 1184 | 0.100 |
Why?
|
| Cyclophosphamide | 2 | 2016 | 2220 | 0.100 |
Why?
|
| Drug Therapy | 1 | 2015 | 504 | 0.100 |
Why?
|
| Credentialing | 1 | 2012 | 115 | 0.100 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2013 | 323 | 0.100 |
Why?
|
| Influenza A virus | 1 | 2015 | 457 | 0.100 |
Why?
|
| Angiotensin II | 5 | 2006 | 850 | 0.100 |
Why?
|
| Hydrochlorothiazide | 2 | 2010 | 94 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1093 | 0.100 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2012 | 142 | 0.100 |
Why?
|
| Thromboembolism | 2 | 2016 | 1016 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2018 | 1617 | 0.100 |
Why?
|
| Enzyme Inhibitors | 5 | 2024 | 3726 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2023 | 151 | 0.100 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 688 | 0.100 |
Why?
|
| Life Expectancy | 2 | 2015 | 1249 | 0.100 |
Why?
|
| Cell Wall | 1 | 2015 | 425 | 0.100 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 6830 | 0.100 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2011 | 31 | 0.100 |
Why?
|
| Anticoagulants | 6 | 2023 | 4896 | 0.100 |
Why?
|
| Statistics, Nonparametric | 4 | 2012 | 2852 | 0.100 |
Why?
|
| Editorial Policies | 1 | 2016 | 457 | 0.100 |
Why?
|
| Malaria | 1 | 2021 | 1226 | 0.100 |
Why?
|
| Life Change Events | 1 | 1997 | 953 | 0.100 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2003 | 265 | 0.100 |
Why?
|
| Europe, Eastern | 2 | 2023 | 72 | 0.100 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2012 | 273 | 0.100 |
Why?
|
| Vaccines, Inactivated | 2 | 2023 | 180 | 0.090 |
Why?
|
| Retinal Vein | 1 | 1991 | 47 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 730 | 0.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 1997 | 4547 | 0.090 |
Why?
|
| Depression | 5 | 2021 | 8033 | 0.090 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2021 | 578 | 0.090 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 125 | 0.090 |
Why?
|
| Child | 21 | 2023 | 79758 | 0.090 |
Why?
|
| Catheter Ablation | 3 | 2020 | 2755 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2023 | 17766 | 0.090 |
Why?
|
| Animals | 35 | 2020 | 167940 | 0.090 |
Why?
|
| Demography | 2 | 2013 | 1650 | 0.090 |
Why?
|
| Life Style | 3 | 2018 | 3888 | 0.090 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2012 | 377 | 0.090 |
Why?
|
| Optic Atrophy | 1 | 1991 | 78 | 0.090 |
Why?
|
| Hyperhomocysteinemia | 1 | 2011 | 118 | 0.090 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2010 | 48 | 0.090 |
Why?
|
| RNA Interference | 1 | 2019 | 2846 | 0.090 |
Why?
|
| Phenylalanine | 1 | 2012 | 365 | 0.090 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2012 | 146 | 0.090 |
Why?
|
| Species Specificity | 1 | 2015 | 2413 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2023 | 3537 | 0.090 |
Why?
|
| Women's Health | 1 | 2000 | 2057 | 0.090 |
Why?
|
| Sensation | 1 | 1992 | 331 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 2906 | 0.090 |
Why?
|
| Atrial Function | 1 | 2010 | 99 | 0.090 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2010 | 43 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2016 | 817 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 5640 | 0.090 |
Why?
|
| Placebo Effect | 3 | 2019 | 511 | 0.090 |
Why?
|
| Benzazepines | 2 | 2010 | 311 | 0.090 |
Why?
|
| Organizational Policy | 1 | 2012 | 429 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 1004 | 0.090 |
Why?
|
| Forecasting | 2 | 2016 | 2931 | 0.090 |
Why?
|
| Myosin Heavy Chains | 2 | 2002 | 402 | 0.090 |
Why?
|
| Radiation Monitoring | 1 | 2010 | 103 | 0.090 |
Why?
|
| Gyrus Cinguli | 1 | 2016 | 1113 | 0.090 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 854 | 0.080 |
Why?
|
| Nerve Compression Syndromes | 1 | 1991 | 160 | 0.080 |
Why?
|
| Macular Edema | 2 | 2012 | 375 | 0.080 |
Why?
|
| Amyloid beta-Peptides | 2 | 2020 | 3839 | 0.080 |
Why?
|
| Radon | 1 | 2010 | 83 | 0.080 |
Why?
|
| Serum Albumin | 2 | 2009 | 674 | 0.080 |
Why?
|
| Benzoates | 1 | 2011 | 212 | 0.080 |
Why?
|
| Frontal Lobe | 1 | 2016 | 1422 | 0.080 |
Why?
|
| Sulfones | 1 | 2012 | 447 | 0.080 |
Why?
|
| Procollagen | 2 | 2023 | 188 | 0.080 |
Why?
|
| Analysis of Variance | 7 | 2014 | 6242 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2019 | 1915 | 0.080 |
Why?
|
| Aspartame | 1 | 1989 | 19 | 0.080 |
Why?
|
| Safety | 2 | 2006 | 1149 | 0.080 |
Why?
|
| Trinidad and Tobago | 1 | 2008 | 12 | 0.080 |
Why?
|
| Genotype | 5 | 2017 | 12959 | 0.080 |
Why?
|
| Blood Urea Nitrogen | 3 | 2024 | 187 | 0.080 |
Why?
|
| Ethylene Glycols | 2 | 2020 | 190 | 0.080 |
Why?
|
| Calcinosis | 1 | 2018 | 1478 | 0.080 |
Why?
|
| Hypercalcemia | 1 | 2012 | 421 | 0.080 |
Why?
|
| Equipment Design | 3 | 2014 | 3520 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2012 | 385 | 0.080 |
Why?
|
| Dilatation, Pathologic | 1 | 2010 | 527 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1067 | 0.080 |
Why?
|
| Heart-Assist Devices | 3 | 2018 | 1290 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2001 | 385 | 0.080 |
Why?
|
| Benzamides | 1 | 2014 | 1369 | 0.080 |
Why?
|
| Choroid | 1 | 1991 | 349 | 0.080 |
Why?
|
| Vitamin B Complex | 1 | 2011 | 297 | 0.080 |
Why?
|
| Angiography | 1 | 2014 | 1605 | 0.080 |
Why?
|
| Attention | 2 | 2016 | 2386 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1999 | 1190 | 0.080 |
Why?
|
| Adrenomedullin | 2 | 2023 | 85 | 0.080 |
Why?
|
| Lipoprotein(a) | 1 | 2013 | 499 | 0.080 |
Why?
|
| Syndrome | 2 | 2014 | 3278 | 0.080 |
Why?
|
| Probucol | 1 | 2008 | 25 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 2002 | 0.080 |
Why?
|
| MicroRNAs | 2 | 2024 | 3784 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2003 | 685 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 1975 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 7803 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2013 | 613 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 1817 | 0.080 |
Why?
|
| Albumins | 1 | 2011 | 577 | 0.080 |
Why?
|
| Natriuresis | 3 | 1977 | 105 | 0.080 |
Why?
|
| Bronchodilator Agents | 2 | 2010 | 506 | 0.080 |
Why?
|
| Contrast Sensitivity | 1 | 2009 | 235 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2021 | 3530 | 0.080 |
Why?
|
| Hydrothorax | 1 | 2007 | 18 | 0.070 |
Why?
|
| Uranium | 1 | 2007 | 23 | 0.070 |
Why?
|
| Medication Adherence | 2 | 2017 | 2163 | 0.070 |
Why?
|
| Molecular Sequence Data | 9 | 2015 | 17628 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2023 | 462 | 0.070 |
Why?
|
| Epoprostenol | 1 | 1989 | 248 | 0.070 |
Why?
|
| Length of Stay | 5 | 2019 | 6472 | 0.070 |
Why?
|
| Radial Artery | 1 | 2009 | 196 | 0.070 |
Why?
|
| Cytokines | 3 | 2020 | 7345 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4573 | 0.070 |
Why?
|
| Heart Transplantation | 2 | 2020 | 3217 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1539 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2023 | 6540 | 0.070 |
Why?
|
| Arteries | 1 | 2012 | 1126 | 0.070 |
Why?
|
| Rats | 19 | 2004 | 23695 | 0.070 |
Why?
|
| Optic Nerve Diseases | 1 | 1991 | 342 | 0.070 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2007 | 49 | 0.070 |
Why?
|
| Wine | 1 | 2008 | 167 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2023 | 366 | 0.070 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 1689 | 0.070 |
Why?
|
| Survivors | 4 | 2014 | 2367 | 0.070 |
Why?
|
| Self Efficacy | 2 | 2023 | 629 | 0.070 |
Why?
|
| Transplantation, Homologous | 5 | 2021 | 4814 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 249 | 0.070 |
Why?
|
| Blood Proteins | 3 | 2020 | 1172 | 0.070 |
Why?
|
| Syncope | 1 | 2010 | 428 | 0.070 |
Why?
|
| Ascomycota | 1 | 2007 | 82 | 0.070 |
Why?
|
| Amaurosis Fugax | 1 | 2006 | 7 | 0.070 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2007 | 129 | 0.070 |
Why?
|
| Piperazines | 2 | 2014 | 2520 | 0.070 |
Why?
|
| Cross Infection | 1 | 1996 | 1434 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 4168 | 0.070 |
Why?
|
| Hospitals | 2 | 2021 | 3929 | 0.070 |
Why?
|
| Manometry | 1 | 2009 | 453 | 0.070 |
Why?
|
| Endothelin-1 | 2 | 2023 | 302 | 0.070 |
Why?
|
| Asymptomatic Diseases | 2 | 2024 | 582 | 0.070 |
Why?
|
| Vision Disorders | 2 | 1992 | 1084 | 0.070 |
Why?
|
| Electrolytes | 1 | 2007 | 280 | 0.070 |
Why?
|
| Psychology | 1 | 2008 | 355 | 0.070 |
Why?
|
| Mental Recall | 3 | 1996 | 1205 | 0.070 |
Why?
|
| Gastrointestinal Tract | 2 | 2013 | 830 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 2 | 2013 | 1189 | 0.070 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2007 | 164 | 0.070 |
Why?
|
| Hematologic Tests | 1 | 2007 | 238 | 0.070 |
Why?
|
| Bombesin | 1 | 1986 | 35 | 0.070 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2007 | 231 | 0.070 |
Why?
|
| Motion | 2 | 2010 | 779 | 0.070 |
Why?
|
| Heart Septum | 2 | 2012 | 303 | 0.070 |
Why?
|
| Evidence-Based Medicine | 3 | 2019 | 3696 | 0.070 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 12602 | 0.070 |
Why?
|
| Space Perception | 1 | 2009 | 464 | 0.070 |
Why?
|
| Calibration | 1 | 2008 | 816 | 0.070 |
Why?
|
| Epidemiologic Methods | 4 | 2016 | 1344 | 0.070 |
Why?
|
| Fibrin | 1 | 1989 | 505 | 0.070 |
Why?
|
| Follicular Phase | 1 | 2006 | 143 | 0.070 |
Why?
|
| Luteal Phase | 1 | 2006 | 138 | 0.070 |
Why?
|
| Aniline Compounds | 3 | 2020 | 1068 | 0.070 |
Why?
|
| Propranolol | 4 | 1983 | 489 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2007 | 524 | 0.070 |
Why?
|
| Cell Fusion | 1 | 2006 | 293 | 0.070 |
Why?
|
| Chromosome Mapping | 6 | 2001 | 4625 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 9196 | 0.070 |
Why?
|
| Asia | 2 | 2018 | 618 | 0.070 |
Why?
|
| Drug-Eluting Stents | 1 | 2012 | 758 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2021 | 3840 | 0.060 |
Why?
|
| Hexuronic Acids | 2 | 2015 | 145 | 0.060 |
Why?
|
| Glucuronic Acid | 2 | 2015 | 150 | 0.060 |
Why?
|
| Sample Size | 3 | 2015 | 840 | 0.060 |
Why?
|
| Ventricular Dysfunction | 1 | 2006 | 145 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2012 | 1430 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2805 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 2422 | 0.060 |
Why?
|
| Sodium, Dietary | 2 | 2006 | 425 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2023 | 5201 | 0.060 |
Why?
|
| Pregnancy | 7 | 2023 | 29725 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 1287 | 0.060 |
Why?
|
| South America | 2 | 2016 | 181 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1797 | 0.060 |
Why?
|
| Pedigree | 8 | 2009 | 4577 | 0.060 |
Why?
|
| Public Health Informatics | 1 | 2006 | 109 | 0.060 |
Why?
|
| Thinness | 1 | 2008 | 491 | 0.060 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1987 | 619 | 0.060 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2006 | 239 | 0.060 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2005 | 479 | 0.060 |
Why?
|
| beta 2-Microglobulin | 2 | 2017 | 328 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2009 | 797 | 0.060 |
Why?
|
| Aspirin | 3 | 2010 | 3365 | 0.060 |
Why?
|
| Adrenal Glands | 4 | 1991 | 556 | 0.060 |
Why?
|
| Mannose-Binding Lectin | 1 | 2005 | 146 | 0.060 |
Why?
|
| Methyldopa | 1 | 1983 | 18 | 0.060 |
Why?
|
| Overweight | 1 | 2015 | 2421 | 0.060 |
Why?
|
| Environmental Monitoring | 1 | 2010 | 1441 | 0.060 |
Why?
|
| Valsalva Maneuver | 1 | 2024 | 98 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 3618 | 0.060 |
Why?
|
| Tricuspid Valve | 1 | 2007 | 409 | 0.060 |
Why?
|
| Sexual Partners | 3 | 2008 | 750 | 0.060 |
Why?
|
| Nerve Net | 1 | 2016 | 2258 | 0.060 |
Why?
|
| Disasters | 1 | 1990 | 518 | 0.060 |
Why?
|
| Diagnosis, Differential | 5 | 2001 | 12968 | 0.060 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2004 | 167 | 0.060 |
Why?
|
| Disopyramide | 1 | 2023 | 16 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 1 | 2009 | 558 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2006 | 474 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 2009 | 955 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2017 | 4423 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 273 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 1919 | 0.060 |
Why?
|
| Health Behavior | 2 | 2019 | 2621 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 1986 | 416 | 0.060 |
Why?
|
| Netherlands | 2 | 2020 | 2213 | 0.060 |
Why?
|
| Smoking Cessation | 2 | 2018 | 2064 | 0.060 |
Why?
|
| Atmosphere | 1 | 2023 | 32 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2017 | 15680 | 0.060 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2003 | 121 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 1989 | 613 | 0.050 |
Why?
|
| Brain | 2 | 2020 | 26912 | 0.050 |
Why?
|
| Blood Volume | 3 | 2010 | 550 | 0.050 |
Why?
|
| Heterosexuality | 1 | 2005 | 294 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2009 | 1968 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 618 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8551 | 0.050 |
Why?
|
| Aptamers, Nucleotide | 1 | 2024 | 171 | 0.050 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 45 | 0.050 |
Why?
|
| Leukocyte Elastase | 1 | 2003 | 114 | 0.050 |
Why?
|
| Angina, Unstable | 3 | 2015 | 926 | 0.050 |
Why?
|
| Commerce | 1 | 2008 | 604 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 258 | 0.050 |
Why?
|
| Vidarabine | 1 | 2003 | 336 | 0.050 |
Why?
|
| Carbamates | 1 | 2024 | 192 | 0.050 |
Why?
|
| Receptors, Erythropoietin | 1 | 2022 | 144 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2003 | 1755 | 0.050 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 3145 | 0.050 |
Why?
|
| Microcirculation | 2 | 2023 | 1279 | 0.050 |
Why?
|
| Atrial Premature Complexes | 1 | 2021 | 17 | 0.050 |
Why?
|
| Reperfusion | 1 | 2023 | 271 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2002 | 252 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2002 | 261 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 210 | 0.050 |
Why?
|
| Colchicine | 1 | 2023 | 261 | 0.050 |
Why?
|
| Acyclovir | 1 | 2002 | 269 | 0.050 |
Why?
|
| Electronics | 1 | 2023 | 317 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 1992 | 1647 | 0.050 |
Why?
|
| Eye Evisceration | 1 | 2001 | 22 | 0.050 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2001 | 28 | 0.050 |
Why?
|
| Attitude to Health | 2 | 2008 | 2028 | 0.050 |
Why?
|
| Psychomotor Agitation | 1 | 2023 | 306 | 0.050 |
Why?
|
| Nitrogen Oxides | 1 | 2021 | 128 | 0.050 |
Why?
|
| Suppuration | 1 | 2000 | 61 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2022 | 291 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2006 | 619 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2016 | 3421 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2003 | 532 | 0.050 |
Why?
|
| Defensins | 3 | 1999 | 34 | 0.040 |
Why?
|
| Bilirubin | 1 | 2022 | 438 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2014 | 3201 | 0.040 |
Why?
|
| Actigraphy | 1 | 2024 | 518 | 0.040 |
Why?
|
| Schools | 1 | 2009 | 1474 | 0.040 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2001 | 209 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2012 | 3561 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 3451 | 0.040 |
Why?
|
| Video Recording | 2 | 2010 | 957 | 0.040 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 1375 | 0.040 |
Why?
|
| Antioxidants | 1 | 2008 | 1668 | 0.040 |
Why?
|
| Indomethacin | 2 | 1992 | 326 | 0.040 |
Why?
|
| Action Potentials | 2 | 2019 | 1814 | 0.040 |
Why?
|
| Health Policy | 1 | 2012 | 2678 | 0.040 |
Why?
|
| Los Angeles | 1 | 2020 | 243 | 0.040 |
Why?
|
| Antilymphocyte Serum | 1 | 2021 | 482 | 0.040 |
Why?
|
| AIDS Serodiagnosis | 1 | 2001 | 216 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1990 | 6017 | 0.040 |
Why?
|
| Cardiomyopathy, Alcoholic | 1 | 2019 | 6 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2023 | 457 | 0.040 |
Why?
|
| Gentamicins | 1 | 2000 | 252 | 0.040 |
Why?
|
| Histamine Release | 1 | 1999 | 137 | 0.040 |
Why?
|
| Porphyrins | 1 | 2001 | 352 | 0.040 |
Why?
|
| Photons | 2 | 2001 | 581 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1990 | 761 | 0.040 |
Why?
|
| Jugular Veins | 1 | 2020 | 211 | 0.040 |
Why?
|
| Asia, Western | 1 | 2018 | 19 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2022 | 858 | 0.040 |
Why?
|
| Dangerous Behavior | 1 | 2019 | 65 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2023 | 1128 | 0.040 |
Why?
|
| Chromatography, Gel | 3 | 1996 | 645 | 0.040 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2021 | 274 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2022 | 787 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 784 | 0.040 |
Why?
|
| Asia, Southeastern | 1 | 2018 | 113 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 1673 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 2178 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 142 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2009 | 2569 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2021 | 628 | 0.040 |
Why?
|
| Rats, Wistar | 2 | 1999 | 1849 | 0.040 |
Why?
|
| Americas | 1 | 2018 | 111 | 0.040 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2001 | 345 | 0.040 |
Why?
|
| Pro-Opiomelanocortin | 2 | 1991 | 140 | 0.040 |
Why?
|
| Health Surveys | 1 | 2008 | 4061 | 0.040 |
Why?
|
| Collagenases | 1 | 1999 | 221 | 0.040 |
Why?
|
| Genes | 3 | 1993 | 1845 | 0.040 |
Why?
|
| Policy | 1 | 2022 | 511 | 0.040 |
Why?
|
| Diuresis | 2 | 1975 | 107 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 2311 | 0.040 |
Why?
|
| Conditioning, Classical | 2 | 2016 | 364 | 0.040 |
Why?
|
| Vectorcardiography | 1 | 2018 | 48 | 0.040 |
Why?
|
| Marriage | 1 | 2000 | 351 | 0.040 |
Why?
|
| Choroidal Neovascularization | 1 | 2001 | 357 | 0.040 |
Why?
|
| alpha-Defensins | 2 | 1999 | 30 | 0.040 |
Why?
|
| Developing Countries | 2 | 2022 | 2880 | 0.040 |
Why?
|
| Coronary Angiography | 4 | 2017 | 4560 | 0.040 |
Why?
|
| Peripartum Period | 1 | 2019 | 138 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1999 | 313 | 0.040 |
Why?
|
| Polysomnography | 2 | 2015 | 1817 | 0.040 |
Why?
|
| Memory | 2 | 1987 | 2179 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2449 | 0.040 |
Why?
|
| Research Personnel | 1 | 2022 | 584 | 0.040 |
Why?
|
| Eye Neoplasms | 1 | 1999 | 306 | 0.040 |
Why?
|
| Thiazoles | 2 | 2016 | 1509 | 0.040 |
Why?
|
| Precipitating Factors | 1 | 2017 | 51 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 2000 | 432 | 0.040 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 1023 | 0.040 |
Why?
|
| Hypophysectomy | 1 | 1977 | 114 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2020 | 458 | 0.040 |
Why?
|
| Penicillins | 1 | 2000 | 403 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 3 | 1992 | 382 | 0.040 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2018 | 131 | 0.040 |
Why?
|
| Metabolome | 1 | 2024 | 976 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 2 | 1975 | 334 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2001 | 616 | 0.040 |
Why?
|
| Mitral Valve Prolapse | 1 | 1999 | 215 | 0.040 |
Why?
|
| Public Health | 2 | 2020 | 2655 | 0.040 |
Why?
|
| Egg Shell | 1 | 1996 | 9 | 0.040 |
Why?
|
| Donor Selection | 1 | 2019 | 228 | 0.040 |
Why?
|
| Femur Head Necrosis | 1 | 1997 | 132 | 0.040 |
Why?
|
| Weight Loss | 1 | 2008 | 2683 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2001 | 1349 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2004 | 5039 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 8008 | 0.030 |
Why?
|
| Models, Biological | 1 | 2013 | 9468 | 0.030 |
Why?
|
| Albuterol | 1 | 1997 | 212 | 0.030 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 413 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 1997 | 213 | 0.030 |
Why?
|
| Chagas Disease | 1 | 2018 | 167 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 1977 | 222 | 0.030 |
Why?
|
| Calcium Carbonate | 1 | 1996 | 62 | 0.030 |
Why?
|
| Ontario | 1 | 2017 | 405 | 0.030 |
Why?
|
| Research Report | 1 | 2019 | 370 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 1882 | 0.030 |
Why?
|
| Paired-Associate Learning | 1 | 1996 | 53 | 0.030 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 337 | 0.030 |
Why?
|
| Prolactin | 2 | 1993 | 621 | 0.030 |
Why?
|
| Radionuclide Ventriculography | 1 | 2015 | 40 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2018 | 238 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2022 | 6543 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2006 | 1780 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 13629 | 0.030 |
Why?
|
| Japan | 1 | 2020 | 1369 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 1952 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 1075 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 831 | 0.030 |
Why?
|
| Animals, Newborn | 2 | 2002 | 2671 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2018 | 361 | 0.030 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2006 | 1634 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 1727 | 0.030 |
Why?
|
| Fundus Oculi | 2 | 2001 | 541 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 316 | 0.030 |
Why?
|
| Killer Cells, Natural | 4 | 1993 | 2204 | 0.030 |
Why?
|
| International Cooperation | 2 | 2013 | 1436 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2019 | 2612 | 0.030 |
Why?
|
| Radiology | 1 | 2009 | 2103 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2016 | 642 | 0.030 |
Why?
|
| Spirometry | 1 | 2018 | 924 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2023 | 1076 | 0.030 |
Why?
|
| Photochemotherapy | 1 | 2001 | 819 | 0.030 |
Why?
|
| Disease Models, Animal | 7 | 2014 | 18134 | 0.030 |
Why?
|
| Information Services | 1 | 1996 | 235 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 1991 | 1549 | 0.030 |
Why?
|
| Infant | 4 | 2022 | 36030 | 0.030 |
Why?
|
| Attitude to Death | 1 | 1998 | 402 | 0.030 |
Why?
|
| Death Certificates | 1 | 2015 | 167 | 0.030 |
Why?
|
| Rats, Inbred Strains | 3 | 1992 | 2094 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2009 | 8553 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 3870 | 0.030 |
Why?
|
| Amnesia | 1 | 2016 | 255 | 0.030 |
Why?
|
| Compliance | 1 | 2014 | 100 | 0.030 |
Why?
|
| Confusion | 1 | 2016 | 277 | 0.030 |
Why?
|
| Face | 1 | 2020 | 1017 | 0.030 |
Why?
|
| Chickens | 1 | 1996 | 859 | 0.030 |
Why?
|
| Thrombosis | 1 | 2008 | 3052 | 0.030 |
Why?
|
| Fluoroscopy | 2 | 2013 | 943 | 0.030 |
Why?
|
| Seasons | 1 | 2020 | 1523 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2015 | 354 | 0.030 |
Why?
|
| Social Perception | 1 | 1998 | 431 | 0.030 |
Why?
|
| Edema | 1 | 2018 | 772 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 107 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2020 | 1576 | 0.030 |
Why?
|
| Eosinophils | 1 | 1998 | 946 | 0.030 |
Why?
|
| Neutrophils | 2 | 1999 | 3770 | 0.030 |
Why?
|
| Genes, Dominant | 2 | 2000 | 863 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2001 | 1128 | 0.030 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 103 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2014 | 173 | 0.030 |
Why?
|
| Antithrombins | 1 | 2016 | 313 | 0.030 |
Why?
|
| Sodium Channel Blockers | 1 | 2014 | 172 | 0.030 |
Why?
|
| Lipocalins | 1 | 2014 | 161 | 0.030 |
Why?
|
| USSR | 1 | 2012 | 19 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2010 | 4668 | 0.030 |
Why?
|
| Cosyntropin | 1 | 1993 | 34 | 0.030 |
Why?
|
| Aorta | 2 | 2014 | 2042 | 0.030 |
Why?
|
| Aggression | 1 | 1998 | 745 | 0.030 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2016 | 277 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2001 | 2937 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 20484 | 0.030 |
Why?
|
| Lod Score | 2 | 1990 | 602 | 0.030 |
Why?
|
| Diclofenac | 1 | 2013 | 67 | 0.030 |
Why?
|
| Hand Deformities, Congenital | 1 | 1994 | 173 | 0.030 |
Why?
|
| Heart Septal Defects | 1 | 1994 | 191 | 0.030 |
Why?
|
| Naproxen | 1 | 2013 | 100 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 7400 | 0.030 |
Why?
|
| Flavoproteins | 1 | 1992 | 40 | 0.030 |
Why?
|
| Drug Approval | 1 | 2020 | 816 | 0.030 |
Why?
|
| Cotinine | 1 | 1993 | 203 | 0.030 |
Why?
|
| Personnel Selection | 1 | 2014 | 193 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 830 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1994 | 553 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1994 | 430 | 0.030 |
Why?
|
| Anthracyclines | 1 | 2014 | 283 | 0.030 |
Why?
|
| Asthma | 3 | 2001 | 6167 | 0.030 |
Why?
|
| Cell Division | 3 | 2003 | 4462 | 0.030 |
Why?
|
| Amino Acid Sequence | 8 | 2000 | 13456 | 0.030 |
Why?
|
| Semantics | 1 | 1996 | 599 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 6131 | 0.030 |
Why?
|
| Hydrodynamics | 1 | 2013 | 167 | 0.020 |
Why?
|
| Acetaminophen | 1 | 1996 | 553 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 1346 | 0.020 |
Why?
|
| Mast Cells | 1 | 1999 | 1428 | 0.020 |
Why?
|
| Israel | 1 | 2014 | 722 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2020 | 2777 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2013 | 555 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 1987 | 13249 | 0.020 |
Why?
|
| Fluorescein Angiography | 2 | 2001 | 1045 | 0.020 |
Why?
|
| Succinate Dehydrogenase | 1 | 1992 | 145 | 0.020 |
Why?
|
| Ergot Alkaloids | 1 | 1991 | 12 | 0.020 |
Why?
|
| Ibuprofen | 1 | 2013 | 229 | 0.020 |
Why?
|
| Ergotamine | 1 | 1991 | 7 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 1447 | 0.020 |
Why?
|
| Heart Injuries | 1 | 2013 | 208 | 0.020 |
Why?
|
| Mothers | 1 | 2022 | 2186 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2023 | 2510 | 0.020 |
Why?
|
| Rabbits | 4 | 1999 | 4773 | 0.020 |
Why?
|
| Aqueous Humor | 1 | 2012 | 154 | 0.020 |
Why?
|
| Health Services | 1 | 1997 | 754 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1008 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 2011 | 114 | 0.020 |
Why?
|
| Massachusetts | 2 | 2015 | 8805 | 0.020 |
Why?
|
| Heparin | 1 | 1999 | 1655 | 0.020 |
Why?
|
| Proteins | 2 | 1999 | 6030 | 0.020 |
Why?
|
| Codon | 1 | 1993 | 602 | 0.020 |
Why?
|
| Pain | 1 | 2006 | 5066 | 0.020 |
Why?
|
| Hematocrit | 2 | 1988 | 630 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 1503 | 0.020 |
Why?
|
| Receptors, Cell Surface | 2 | 2016 | 2825 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2000 | 1089 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2022 | 26168 | 0.020 |
Why?
|
| Pyridones | 1 | 2016 | 788 | 0.020 |
Why?
|
| Myosin Subfragments | 1 | 1990 | 20 | 0.020 |
Why?
|
| Genes, Fungal | 1 | 1992 | 439 | 0.020 |
Why?
|
| Scotoma | 1 | 1992 | 130 | 0.020 |
Why?
|
| Ophthalmic Solutions | 1 | 2012 | 305 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1993 | 389 | 0.020 |
Why?
|
| Bone Marrow | 2 | 2019 | 2918 | 0.020 |
Why?
|
| Alpha Particles | 1 | 2010 | 29 | 0.020 |
Why?
|
| Drug Industry | 1 | 2017 | 789 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 1628 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 1990 | 260 | 0.020 |
Why?
|
| Automation | 1 | 2013 | 581 | 0.020 |
Why?
|
| Analog-Digital Conversion | 1 | 2010 | 23 | 0.020 |
Why?
|
| Polyethylene Terephthalates | 1 | 2010 | 115 | 0.020 |
Why?
|
| Body Fluids | 3 | 2007 | 319 | 0.020 |
Why?
|
| Radioimmunoassay | 2 | 1993 | 866 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2016 | 1108 | 0.020 |
Why?
|
| Glycopeptides | 1 | 2011 | 220 | 0.020 |
Why?
|
| Missouri | 1 | 1990 | 114 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2018 | 1174 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 1991 | 257 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2000 | 1343 | 0.020 |
Why?
|
| Depressive Disorder | 2 | 1995 | 3728 | 0.020 |
Why?
|
| Genetic Markers | 3 | 2002 | 2608 | 0.020 |
Why?
|
| Critical Illness | 1 | 2023 | 2709 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 8945 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 418 | 0.020 |
Why?
|
| Cells, Cultured | 5 | 2006 | 18968 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2022 | 4223 | 0.020 |
Why?
|
| Vitreous Body | 1 | 2012 | 399 | 0.020 |
Why?
|
| Hydrogels | 1 | 2015 | 725 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2006 | 2056 | 0.020 |
Why?
|
| Nature | 1 | 2009 | 15 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2002 | 3061 | 0.020 |
Why?
|
| Dioxins | 1 | 1990 | 92 | 0.020 |
Why?
|
| Office Visits | 1 | 1994 | 597 | 0.020 |
Why?
|
| Regional Blood Flow | 2 | 2007 | 1490 | 0.020 |
Why?
|
| Australia | 1 | 2013 | 1288 | 0.020 |
Why?
|
| Cytochalasins | 1 | 1989 | 19 | 0.020 |
Why?
|
| Hallucinations | 1 | 1992 | 366 | 0.020 |
Why?
|
| Trifluoperazine | 1 | 1989 | 37 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2017 | 1056 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 1995 | 781 | 0.020 |
Why?
|
| Ethanol | 2 | 2001 | 1323 | 0.020 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1989 | 80 | 0.020 |
Why?
|
| Perceptual Masking | 1 | 2009 | 90 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2004 | 7854 | 0.020 |
Why?
|
| Reward | 1 | 2016 | 964 | 0.020 |
Why?
|
| Cytochalasin D | 1 | 1989 | 91 | 0.020 |
Why?
|
| Fear | 1 | 1998 | 1462 | 0.020 |
Why?
|
| Secretory Rate | 1 | 1968 | 81 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2006 | 11480 | 0.020 |
Why?
|
| Puerto Rico | 1 | 1990 | 373 | 0.020 |
Why?
|
| Saliva | 1 | 1993 | 816 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 2167 | 0.020 |
Why?
|
| Schizophrenic Psychology | 1 | 1996 | 1646 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2016 | 1032 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 2297 | 0.020 |
Why?
|
| Hydrocortisone | 2 | 1993 | 1798 | 0.020 |
Why?
|
| Joint Instability | 1 | 1996 | 795 | 0.020 |
Why?
|
| Dactinomycin | 1 | 1989 | 306 | 0.020 |
Why?
|
| Cycloheximide | 1 | 1989 | 343 | 0.020 |
Why?
|
| Trichomonas Vaginitis | 1 | 2008 | 33 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2018 | 2618 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 1991 | 637 | 0.020 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 1992 | 367 | 0.020 |
Why?
|
| Point Mutation | 1 | 1994 | 1594 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 1989 | 426 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2019 | 1939 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 377 | 0.020 |
Why?
|
| Motivation | 1 | 1998 | 1990 | 0.020 |
Why?
|
| Walking | 1 | 2015 | 1190 | 0.020 |
Why?
|
| Nephrons | 3 | 1977 | 168 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2017 | 8018 | 0.020 |
Why?
|
| South Africa | 1 | 2013 | 1821 | 0.020 |
Why?
|
| Condoms | 1 | 2009 | 315 | 0.020 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 810 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2013 | 1112 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2007 | 197 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2014 | 920 | 0.020 |
Why?
|
| Vinblastine | 1 | 1989 | 487 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2019 | 2500 | 0.020 |
Why?
|
| Herpes Genitalis | 1 | 2008 | 142 | 0.020 |
Why?
|
| Mining | 1 | 2007 | 91 | 0.020 |
Why?
|
| Spouses | 1 | 2009 | 279 | 0.020 |
Why?
|
| Herpesvirus 2, Human | 1 | 2008 | 190 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 8157 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 1612 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 1987 | 257 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 1295 | 0.020 |
Why?
|
| Lipids | 1 | 2018 | 3336 | 0.020 |
Why?
|
| Menstruation | 1 | 1968 | 307 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 2011 | 1064 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2013 | 760 | 0.020 |
Why?
|
| Graft Survival | 1 | 2017 | 3793 | 0.020 |
Why?
|
| Nucleosides | 1 | 1987 | 131 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1992 | 3086 | 0.020 |
Why?
|
| Pleura | 1 | 2007 | 243 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2019 | 3737 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2007 | 320 | 0.020 |
Why?
|
| Corticosterone | 1 | 1987 | 303 | 0.020 |
Why?
|
| Renal Circulation | 1 | 2006 | 292 | 0.020 |
Why?
|
| Complement C2 | 1 | 2005 | 70 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 1088 | 0.020 |
Why?
|
| Family Practice | 1 | 1968 | 512 | 0.020 |
Why?
|
| Complement Factor D | 1 | 2005 | 66 | 0.020 |
Why?
|
| Complement Pathway, Mannose-Binding Lectin | 1 | 2005 | 28 | 0.020 |
Why?
|
| Syphilis | 1 | 2008 | 240 | 0.020 |
Why?
|
| Complement Pathway, Classical | 1 | 2005 | 92 | 0.020 |
Why?
|
| Complement Factor B | 1 | 2005 | 72 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 4317 | 0.020 |
Why?
|
| Hospitals, Special | 1 | 2006 | 90 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2010 | 1426 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 1256 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9274 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2009 | 826 | 0.020 |
Why?
|
| Complement Pathway, Alternative | 1 | 2005 | 116 | 0.020 |
Why?
|
| Complement C1q | 1 | 2005 | 94 | 0.020 |
Why?
|
| Elasticity | 1 | 2007 | 652 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1997 | 2160 | 0.020 |
Why?
|
| Delirium | 1 | 2016 | 1651 | 0.020 |
Why?
|
| Retreatment | 1 | 2006 | 600 | 0.020 |
Why?
|
| Base Sequence | 5 | 1994 | 12447 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 1188 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 2394 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 365 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1989 | 1201 | 0.010 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 1999 | 355 | 0.010 |
Why?
|
| Hydroxides | 1 | 1984 | 46 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 1993 | 1655 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 2 | 2006 | 2660 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1784 | 0.010 |
Why?
|
| Peer Group | 1 | 2009 | 674 | 0.010 |
Why?
|
| Integrases | 1 | 2006 | 516 | 0.010 |
Why?
|
| Brain Mapping | 2 | 2016 | 6562 | 0.010 |
Why?
|
| Observation | 1 | 2006 | 312 | 0.010 |
Why?
|
| Immunoglobulin E | 2 | 2001 | 1493 | 0.010 |
Why?
|
| Retroviridae | 1 | 2006 | 850 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2009 | 1000 | 0.010 |
Why?
|
| Age of Onset | 2 | 2005 | 3302 | 0.010 |
Why?
|
| Biological Assay | 1 | 1987 | 630 | 0.010 |
Why?
|
| Boston | 1 | 2016 | 9282 | 0.010 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2003 | 37 | 0.010 |
Why?
|
| Sodium Chloride | 2 | 1976 | 596 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1991 | 1266 | 0.010 |
Why?
|
| Amino Acids | 2 | 1987 | 1715 | 0.010 |
Why?
|
| Disclosure | 1 | 2009 | 738 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2003 | 248 | 0.010 |
Why?
|
| Urban Health | 1 | 2006 | 533 | 0.010 |
Why?
|
| Homeostasis | 1 | 2014 | 3305 | 0.010 |
Why?
|
| Nuclease Protection Assays | 1 | 2002 | 15 | 0.010 |
Why?
|
| Psychotherapy | 1 | 1992 | 1640 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2006 | 1649 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2017 | 3976 | 0.010 |
Why?
|
| Psychometrics | 2 | 1990 | 3049 | 0.010 |
Why?
|
| Phorbol Esters | 1 | 2002 | 108 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 1993 | 1809 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2008 | 701 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2007 | 1833 | 0.010 |
Why?
|
| Femoral Artery | 1 | 2007 | 831 | 0.010 |
Why?
|
| Health Education | 1 | 2009 | 1049 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 826 | 0.010 |
Why?
|
| Isoantigens | 1 | 1984 | 552 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 3 | 2006 | 22025 | 0.010 |
Why?
|
| Metabolism | 1 | 1963 | 193 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2002 | 148 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2004 | 364 | 0.010 |
Why?
|
| Paracrine Communication | 1 | 2003 | 278 | 0.010 |
Why?
|
| Acetic Acid | 1 | 2001 | 60 | 0.010 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1963 | 291 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 2002 | 243 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 835 | 0.010 |
Why?
|
| Cyclin D | 1 | 2001 | 72 | 0.010 |
Why?
|
| Giant Cell Arteritis | 1 | 1985 | 296 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1992 | 2702 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2001 | 221 | 0.010 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2006 | 498 | 0.010 |
Why?
|
| Verbal Learning | 1 | 1983 | 462 | 0.010 |
Why?
|
| Blotting, Southern | 2 | 1993 | 778 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1983 | 639 | 0.010 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2000 | 21 | 0.010 |
Why?
|
| Viral Matrix Proteins | 1 | 2002 | 197 | 0.010 |
Why?
|
| Growth Substances | 1 | 2003 | 768 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 1996 | 4361 | 0.010 |
Why?
|
| Cyclin E | 1 | 2001 | 157 | 0.010 |
Why?
|
| Kinetics | 1 | 1989 | 6378 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1991 | 2731 | 0.010 |
Why?
|
| Artifacts | 1 | 2009 | 1893 | 0.010 |
Why?
|
| Parents | 1 | 2014 | 3547 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1993 | 1351 | 0.010 |
Why?
|
| Yttrium Radioisotopes | 1 | 2001 | 107 | 0.010 |
Why?
|
| Virus Activation | 1 | 2002 | 319 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 2061 | 0.010 |
Why?
|
| Viral Load | 1 | 2009 | 3323 | 0.010 |
Why?
|
| Mass Screening | 2 | 2009 | 5422 | 0.010 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2000 | 88 | 0.010 |
Why?
|
| Clone Cells | 1 | 2003 | 1663 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1999 | 154 | 0.010 |
Why?
|
| Saralasin | 2 | 1976 | 34 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 1999 | 176 | 0.010 |
Why?
|
| Skin Tests | 1 | 2001 | 637 | 0.010 |
Why?
|
| DNA Primers | 2 | 1994 | 2819 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2003 | 1340 | 0.010 |
Why?
|
| Laser Coagulation | 1 | 2001 | 327 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1999 | 142 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 1395 | 0.010 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 1958 | 21 | 0.010 |
Why?
|
| Cyclins | 1 | 2001 | 593 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1992 | 7016 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1999 | 366 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1999 | 200 | 0.010 |
Why?
|
| Ultrasonic Therapy | 1 | 2001 | 215 | 0.010 |
Why?
|
| Lysophospholipids | 1 | 2001 | 339 | 0.010 |
Why?
|
| Ischemic Attack, Transient | 1 | 1984 | 899 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 1250 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 1133 | 0.010 |
Why?
|
| Urography | 1 | 2000 | 312 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 2628 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 5782 | 0.010 |
Why?
|
| Macromolecular Substances | 2 | 1991 | 1433 | 0.010 |
Why?
|
| Kidney Tubules | 2 | 1977 | 449 | 0.010 |
Why?
|
| Adrenal Cortex | 1 | 1958 | 134 | 0.010 |
Why?
|
| Trypsin | 2 | 1991 | 496 | 0.010 |
Why?
|
| Iodine | 1 | 1960 | 286 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 656 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2002 | 756 | 0.010 |
Why?
|
| Liver Failure | 1 | 2000 | 249 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3735 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1984 | 1558 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1999 | 1314 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2002 | 680 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1984 | 1765 | 0.010 |
Why?
|
| Defense Mechanisms | 1 | 1998 | 180 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2006 | 1656 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 1905 | 0.010 |
Why?
|
| Radiotherapy, Conformal | 1 | 2001 | 549 | 0.010 |
Why?
|
| Urinary Tract | 1 | 2001 | 309 | 0.010 |
Why?
|
| Schizophrenia | 1 | 1996 | 6915 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1977 | 116 | 0.010 |
Why?
|
| Punishment | 1 | 1998 | 95 | 0.010 |
Why?
|
| HLA Antigens | 1 | 2003 | 1369 | 0.010 |
Why?
|
| Water | 2 | 1977 | 1402 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1993 | 4172 | 0.010 |
Why?
|
| Alleles | 2 | 1998 | 6900 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 3378 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1960 | 1032 | 0.010 |
Why?
|
| Imagination | 1 | 1998 | 226 | 0.010 |
Why?
|
| Family Health | 1 | 2001 | 1258 | 0.010 |
Why?
|
| Imidazoles | 1 | 2002 | 1178 | 0.010 |
Why?
|
| Diphenylamine | 1 | 1976 | 49 | 0.010 |
Why?
|
| Pregnancy, Animal | 1 | 1976 | 124 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 345 | 0.010 |
Why?
|
| Lymphoma, Follicular | 1 | 1960 | 453 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1996 | 281 | 0.010 |
Why?
|
| GTP Phosphohydrolases | 1 | 1999 | 516 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 1705 | 0.010 |
Why?
|
| Hypotonic Solutions | 1 | 1975 | 49 | 0.010 |
Why?
|
| Curriculum | 1 | 2009 | 3722 | 0.010 |
Why?
|
| Cryosurgery | 1 | 2001 | 473 | 0.010 |
Why?
|
| Guanidines | 1 | 1996 | 193 | 0.010 |
Why?
|
| Tuberculosis | 1 | 2008 | 2003 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1999 | 633 | 0.010 |
Why?
|
| Presbycusis | 1 | 1995 | 43 | 0.010 |
Why?
|
| Extracellular Space | 1 | 1977 | 565 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 11902 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2003 | 1347 | 0.010 |
Why?
|
| Vasopressins | 1 | 1976 | 355 | 0.010 |
Why?
|
| Heme | 1 | 1977 | 313 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2006 | 2877 | 0.010 |
Why?
|
| Audiometry | 1 | 1995 | 253 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 2214 | 0.010 |
Why?
|
| Cell Line | 2 | 2004 | 15626 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2002 | 3605 | 0.010 |
Why?
|
| Glutamine | 1 | 1997 | 576 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1998 | 1600 | 0.010 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1976 | 183 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1996 | 941 | 0.010 |
Why?
|
| DNA Replication | 1 | 2001 | 1412 | 0.010 |
Why?
|
| Progesterone | 1 | 1958 | 742 | 0.010 |
Why?
|
| Macular Degeneration | 1 | 2001 | 1003 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 1746 | 0.010 |
Why?
|
| Eosinophilia | 1 | 1998 | 560 | 0.010 |
Why?
|
| Arginine | 1 | 1997 | 934 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 21065 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2001 | 2656 | 0.010 |
Why?
|
| Mice | 3 | 2006 | 81216 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2002 | 12762 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1960 | 1505 | 0.010 |
Why?
|
| Delusions | 1 | 1995 | 298 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2002 | 2441 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 3604 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2001 | 1240 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1993 | 322 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1960 | 1183 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1960 | 1378 | 0.010 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1996 | 529 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11064 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 1997 | 1996 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 5301 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1995 | 988 | 0.010 |
Why?
|
| Leukemia | 1 | 1960 | 1522 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1997 | 1166 | 0.010 |
Why?
|
| Visual Acuity | 1 | 2001 | 2635 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1987 | 10183 | 0.010 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 32 | 0.010 |
Why?
|
| Methysergide | 1 | 1991 | 28 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 1992 | 279 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1996 | 2509 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1984 | 3046 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2000 | 2563 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 1056 | 0.010 |
Why?
|
| Glycerol | 1 | 1992 | 277 | 0.010 |
Why?
|
| Fetus | 1 | 1958 | 1859 | 0.010 |
Why?
|
| Politics | 1 | 1998 | 815 | 0.010 |
Why?
|
| Lymphoma | 1 | 1960 | 1899 | 0.010 |
Why?
|
| Androgens | 1 | 1958 | 1289 | 0.010 |
Why?
|
| Hip Joint | 1 | 1997 | 1006 | 0.010 |
Why?
|
| Cluster Headache | 1 | 1991 | 54 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2003 | 3390 | 0.010 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 1991 | 240 | 0.010 |
Why?
|
| Physicians | 1 | 1968 | 4590 | 0.010 |
Why?
|
| Hippocampus | 1 | 1983 | 3737 | 0.010 |
Why?
|
| DNA | 2 | 1990 | 7236 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2001 | 8314 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1958 | 1902 | 0.010 |
Why?
|
| Dopamine | 1 | 1977 | 1583 | 0.010 |
Why?
|
| Lymphokines | 1 | 1993 | 929 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1990 | 852 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 14396 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1992 | 652 | 0.010 |
Why?
|
| Reaction Time | 1 | 1996 | 2075 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1994 | 1493 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 4923 | 0.010 |
Why?
|
| Norethynodrel | 1 | 1968 | 1 | 0.010 |
Why?
|
| Mestranol | 1 | 1968 | 8 | 0.010 |
Why?
|
| Pregnanediol | 1 | 1968 | 18 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1991 | 2186 | 0.010 |
Why?
|
| Ascites | 1 | 1971 | 338 | 0.010 |
Why?
|
| DNA Probes | 1 | 1989 | 551 | 0.000 |
Why?
|
| Sequence Alignment | 1 | 1993 | 2178 | 0.000 |
Why?
|
| Deuterium | 1 | 1968 | 105 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1989 | 375 | 0.000 |
Why?
|
| Chemistry, Clinical | 1 | 1968 | 64 | 0.000 |
Why?
|
| Students | 1 | 1998 | 1722 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1977 | 2415 | 0.000 |
Why?
|
| Cell Separation | 1 | 1993 | 1720 | 0.000 |
Why?
|
| England | 1 | 1968 | 526 | 0.000 |
Why?
|
| Biological Transport | 1 | 1992 | 2087 | 0.000 |
Why?
|
| Ischemia | 1 | 1976 | 1893 | 0.000 |
Why?
|
| Perfusion | 1 | 1992 | 1376 | 0.000 |
Why?
|
| Diphtheria | 1 | 1947 | 33 | 0.000 |
Why?
|
| House Calls | 1 | 1968 | 160 | 0.000 |
Why?
|
| Spleen | 1 | 1993 | 2298 | 0.000 |
Why?
|
| Homosexuality | 1 | 1987 | 261 | 0.000 |
Why?
|
| Contraceptives, Oral | 1 | 1968 | 554 | 0.000 |
Why?
|
| Cystine | 1 | 1986 | 94 | 0.000 |
Why?
|
| Cattle | 1 | 1991 | 3847 | 0.000 |
Why?
|
| Protein Multimerization | 1 | 1990 | 983 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1984 | 152 | 0.000 |
Why?
|
| Child, Preschool | 2 | 2000 | 42034 | 0.000 |
Why?
|
| Blood Sedimentation | 1 | 1985 | 234 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 6067 | 0.000 |
Why?
|
| Macrophages | 1 | 1999 | 5745 | 0.000 |
Why?
|
| Disulfides | 1 | 1986 | 466 | 0.000 |
Why?
|
| Nictitating Membrane | 1 | 1983 | 9 | 0.000 |
Why?
|
| Free Radicals | 1 | 1984 | 238 | 0.000 |
Why?
|
| Catalase | 1 | 1984 | 216 | 0.000 |
Why?
|
| Arachidonic Acids | 1 | 1984 | 294 | 0.000 |
Why?
|
| Scopolamine | 1 | 1983 | 94 | 0.000 |
Why?
|
| Autopsy | 1 | 1947 | 1007 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 11708 | 0.000 |
Why?
|
| Speech Perception | 1 | 1987 | 505 | 0.000 |
Why?
|
| Endopeptidases | 1 | 1986 | 772 | 0.000 |
Why?
|
| Sheep | 1 | 1984 | 1441 | 0.000 |
Why?
|
| Swine | 1 | 1991 | 5902 | 0.000 |
Why?
|
| Superoxide Dismutase | 1 | 1984 | 594 | 0.000 |
Why?
|
| Prednisone | 1 | 1985 | 1566 | 0.000 |
Why?
|
| Memory, Short-Term | 1 | 1987 | 977 | 0.000 |
Why?
|
| Hydrogen Peroxide | 1 | 1984 | 732 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 1996 | 5755 | 0.000 |
Why?
|
| Educational Status | 1 | 1987 | 2512 | 0.000 |
Why?
|
| Myocarditis | 1 | 1947 | 766 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1986 | 3969 | 0.000 |
Why?
|
| Loop of Henle | 1 | 1976 | 38 | 0.000 |
Why?
|
| Inulin | 1 | 1976 | 68 | 0.000 |
Why?
|
| Kidney Cortex | 1 | 1976 | 169 | 0.000 |
Why?
|
| Oils | 1 | 1976 | 56 | 0.000 |
Why?
|
| Hydrostatic Pressure | 1 | 1976 | 95 | 0.000 |
Why?
|
| Software | 1 | 1989 | 4420 | 0.000 |
Why?
|
| Uremia | 1 | 1976 | 201 | 0.000 |
Why?
|
| Oxygen | 1 | 1984 | 4189 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1966 | 6182 | 0.000 |
Why?
|